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ABSTRACT OF DISSERTATION

AN INVESTIGATION OF PERINATAL POLYCHLORINATED BIPHENYL
EXPOSURE ON BODY COMPOSITION AND GLUCOSE HOMEOSTASIS
Recent advancements have uncovered environmental contributions to obesity and
diabetes etiology. In fact, perinatal malnutrition resulting in low birth weight (LBW) has
been shown to correlate with later life obesity and impaired glucose tolerance in aged
offspring. LBW can result from a myriad of developmental perturbations including
macronutrient restriction, hypoxia, maternal stress and toxin exposure.
Polychlorinated biphenyls (PCBs) are ubiquitous environmental pollutants that
bioaccumulate in the food chain resulting in dietary exposure in humans. Maternal and
cord blood PCB levels are inversely associated with birth weight, and recent studies
indicate that perinatal exposures to PCBs contribute to gender-specific obesity
development in children. PCBs have also been shown to enter breast milk resulting in
direct exposure in early postnatal life. Therefore, we hypothesized that perinatal PCB
exposure cause developmental blight resulting in decreased birth weight and increased
adiposity and glucose intolerance with aging. We found that mice perinatally exposed to
PCBs did not differ in birth weight, but exhibited sex-specific effects on adiposity.
Females perinatally exposed to PCBs were significantly more obese at 7 weeks of age
while male offspring exhibited no difference in fat mass but had decreased lean mass
compared to controls. With aging, the differences in females dissipated while the male
offspring decreased lean mass persisted. Male offspring perinatally exposed to PCBs
displayed impaired glucose tolerance at 7 weeks of age but normalized over time, while
the females were glucose intolerant only after 6 months of age. This impairment of
glucose tolerance was not attributed to insulin resistance. These data illustrate timedependent and sex-specific perturbations of maternal PCB exposure on offspring body
composition and glucose homeostasis.
As the liver is a major facilitator in glucose homeostasis and xenobiotic
detoxification, we investigated PCB-induced alterations in hepatic gene expression and

found attenuated expression of glycolytic genes and increased expression of detoxifying
and antioxidant genes in both PCB-exposed maternal and offspring livers. Taken
together, these data demonstrate a role for perinatal pollutant exposure in the etiology of
glucose intolerance. Further studies are required to elucidate the mechanisms causing
sex-specific modulation of body composition and glucose intolerance.
Keywords: polychlorinated biphenyls, obesity, diabetes, developmental programming,
environmental pollutants
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CHAPTER 1
INTRODUCTION
1.1 Diabetes
1.1.1 Diabetes in America and the Clinic Diabetes is a chronic noncommunicable
disease characterized by hyperglycemia beyond a normal range. A hormone, insulin, is
secreted by the pancreas in response to a meal and signals for glucose transporters to be
translocated to cell surface of skeletal muscles and adipose tissue to facilitate transport
into the cells from the periphery. By doing so, blood glucose levels decrease. The liver,
too, takes up glucose thereby decreasing blood glucose levels. Diabetes is an inability to
modulate blood glucose by either lack of insulin secretion, an inefficient response to
insulin by peripheral tissues, but most commonly, a combination of the two. Diabetes is
clinically characterized as having fasted blood glucose levels over 126 mg/dL or blood
glucose of over 200 mg/dL following a 2 hour oral glucose challenge while normal levels
are <100 and <140 mg/dL, respectively [1, 2]. Blood glucose levels above normal but
below diabetes criteria are called prediabetes, and patients are characterized as having
either impaired fasting glucose (IFG) or impaired glucose tolerance (IGT). Prediabetics
have an increased risk of developing overt diabetes if lifestyle interventions are not
adopted [2].
Diabetes affects over 340 million people worldwide and 25 million of those are in
the United States. In The United States, the prevalence of diabetes has increased over the
past 20 years [1, 3]. Over 8% of Americans have diabetes and it is estimated that 1 in 3
Americans born after the year 2000 will develop diabetes in their lifetime [1, 4]. This
1

disease has cost the United States an estimated $245 billion dollars in 2012, up 39% from
2007, and $174 billion dollars are from direct medical costs [5]. Moreover, diabetes is
associated with various serious comorbidities such as hypertension, stroke, heart disease
and renal failure. In addition, it is the leading cause of non-traumatic limb amputations,
and a major cause of blindness [1].
There are two types of diabetes, Type 1 diabetes, or insulin-dependent diabetes,
which occurs primarily in children and is an autoimmune disease causing destruction of
insulin-VHFUHWLQJ SDQFUHDWLF ȕ-cells.

Treatment is administration of insulin via

subcutaneous injection [2]. The second and more prevalent type is type 2 diabetes
mellitus (T2DM), or insulin-independent diabetes. T2DM is different from Type 1 in
that it is not caused by immunological ȕ-cell destruction, but rather by an inability of
insulin to solicit its normal glucoregulatory response [6]. This inability of insulin to
influence glucose homeostasis is referred to as insulin resistance. To compensate, the
SDQFUHDWLF ȕ-cells hypertrophy in an attempt to secrete enough insulin to elicit an
HIIHFWLYHUHVSRQVHDQGLQGRLQJVRHYHQWXDOO\OHDGVWRȕ-cell destruction [7]. Ninety-five
to 99% of all diabetes cases in the United States are T2DM, and there are behaviors that
can increase and, fortunately, others that can decrease the risk of developing this type of
diabetes [1].
One risk factor for T2DM is excessive weight gain. Particularly individuals who
are overweight and obese have increased rates of diabetes [8, 9]. Physical inactivity is
also a risk factor for developing diabetes [10-12]. This could be a confounding factor
since physical inactivity is also a cause for overweight and obesity.

Interestingly

however, exercise and healthy diet, even in overweight individuals can decrease the risk
2

of developing diabetes, and this is independent of weight loss [13]. Poor diet can also
lead to the development of diabetes, particularly diets high in fat and simple sugars [6].
Western diets, those high in saturated fats, refined carbohydrates and low in
micronutrients, are particularly keen to the development of diabetes. This points to the
fact that the specific macronutrients are important as to whether glucose intolerance will
result, as certain fats are protective while others are not [14, 15]. Finally, tobacco
smoking is a major risk factor for diabetes [16, 17]. Luckily, these risk factors are mostly
modifiable, such that if one adopts healthy lifestyle changes including a healthy diet and
consistent exercise and cessation of tobacco use, one can greatly reduce his/her risk of
developing this chronic disease.
There are additional risk factors that are not modifiable, those being male gender,
certain ethnicities and age [18, 19]. Further, there is a rather large and unknown genetic
component in T2DM etiology as concordance in identical twins is 90% although the
genetic contribution is determined to be only 10% [20, 21]. Also, Americans from
African and Hispanic descent develop the disease at higher rates than those of European
and Asian descent [18]. Finally, there is evidence that diabetes risk can be affected by
the intrauterine environment as determined by the maternal and developmental influences
[22]. This idea that that the intrauterine environment can “program” the developing fetus
and have long-term health consequences on offspring is called the Developmental
Origins of Health and Disease (DOHaD) Hypothesis. This hypothesis is fundamental to
my dissertation and will be discussed fully in the upcoming sections.
1.1.2 Glucose homeostasis: Overview Upon ingestion of a meal, carbohydrates
are broken down to their simplest sugars, monosacchrides. This digestion begins with
3

salivary and pancreatic amylase [23]. Villus enterocytes of the duodenum and jejunum
produce hydrolases on their brush-border membrane which further digest carbohydrates
into their monomeric sugars [23]. Absorption into enterocytes is carried out by sodiummonosaccharide cotransporter, SGLT1. Sugars exit the cells at the basal lateral membrane
via sodium-independent transporter, glucose transporter 2 (GLUT2) and enter blood
stream via the portal vein [23]. Under normal conditions, the increased blood sugar then
signals the pancreas to secrete insulin, an endocrine hormone whose function is to initiate
glucose uptake from the blood stream into peripheral tissues to meet energy
requirements. Glucose uptake is mediated by glucose transporters (GLUTs), the main
ones being GLUT1, GLUT2, GLUT3 and GLUT4 [6]. GLUT1 is ubiquitously expressed
and is a moderate affinity, low capacity transporter of glucose, while GLUT2 is a low
affinity, high capacity transporter expressed primarily in the intestine, kidneys, pancreas,
and liver [6]. GLUT4 is an insulin-dependent glucose transporter whose expression
facilitates glucose uptake in highly metabolic tissues of skeletal muscle and adipose [6].
When insulin binds its receptor, signal transduction results in the translocation of
cytoplasmic GLUT4 to the cellular membrane where it transports glucose from the
bloodstream into its respective tissue. Type 2 diabetes is often caused by a defect in this
insulin-dependent glucose uptake mechanism, particularly the insulin signal transduction.
In addition to insulin’s role in peripheral glucose uptake, attenuated insulin signal
transduction in the liver can lead to augmented hepatic glucose production and impaired
adipose free fatty acid (FFA) uptake further elevating blood glucose levels and
exacerbating glucose intolerance.

4

1.1.3 Insulin secretion and function Insulin is the primary mediator of glucose
tolerance. The ȕ-cells of the Islets of Langerhans take up glucose from the blood by way
of GLUT2. Once inside the ȕ-cell, glucose undergoes the normal process of glycolysis,
providing substrates for mitochondrial respiration. The increased intracellular ATP:AMP
ratio begins a signaling cascade that results in depolarization of the cellular membrane,
increased cytosolic calcium concentration and degranulation of stored insulin into the
blood for systemic circulation [24].
There are insulin secretagogues that modulate insulin secretion, some being
sympathetic and parasympathetic innervations, but of particular interest in normal
glucose homeostasis, are incretin gut hormones, gastric inhibitory peptide (GIP) and
glucagon-like peptide 1 (GLP-1) [25]. GIP and GLP-1 are secreted prandially by K and
L cells of the intestine, respectively [26, 27].

These incretins potentiate glucose-

stimulated insulin secretion, but they are rapidly degraded by dipeptidyl peptidase 4
(DPP4). Fifty percent of GLP-1 is degraded even before it reaches the portal vein, and an
additional 40% is degraded in the liver [28-32]. In fact, the half-life of GLP-1 is only 6090 seconds.

GLP-1 also inhibits ȕ-cell apoptosis and promotes ȕ-cell survival and

proliferation [33, 34]. In T2DM patients, GIP insulinotropic activity has been shown to
be diminished by 54% and GLP-1 prandial release is attenuated [25, 35-38]. These
incretins are being investigated for their potential use as anti-diabetic agents because their
effects on augmenting insulin secretion are absent when blood sugar levels are low,
thereby decreasing the risk of life-threatening hypoglycemia [39, 40]. Once insulin is
secreted from the ȕ-cell into the systemic circulation, its actions in glucose regulation are
mediated by insulin receptors on liver, skeletal muscle and adipose tissue.
5

The insulin receptor is a receptor tyrosine kinase.

Upon ligand binding,

autophosphorylation of the ȕ subunit of the insulin receptor occurs [41-43]. Insulin
receptor substrate (IRS) is recruited to the activated receptor and is itself phosphorylated
[44].

Phosphorylated IRS then interacts with p85, the regulatory subunit of

phosphotidylinositol 3 kinase (PI3K), targeting the enzyme to the plasma membrane [44,
45]. The product of this enzyme’s activity is phosphotidylinositol 3,4,5,-triphosphate
(PIP3). This molecule then recruits and activates other kinases including protein kinase C
(PKC) ȗDQGprotein kinase B (Akt) [46, 47]. Insulin signaling results in several events
including translocation of GLUT4-containing intracellular vesicles to the plasma
membrane in skeletal muscle and adipose tissue to facilitate glucose uptake [42]. In liver,
insulin signaling deactivates glycogen synthase kinase 3 (GSK3) leading to the
disinhibition of glycogen synthase, thereby increasing glycogen storage and quelling
hepatic glucose production [48, 49]. Insulin resistance occurs when circulating insulin no
longer elicits glucose normalizing responses.

As previously mentioned, as insulin

insensitivity progresses, the SDQFUHDWLF ȕ FHOOV K\SHUWURSK\ DQG HYHQWXDOO\ FDXVH ȕ FHOO
dysfunction and apoptosis and insulin deficiency [50].
1.1.4 Role of adipose, liver and muscle in glucose intolerance Insulin resistance
can result from increased free fatty acid metabolism and ceramide production or also
from inflammation [50-57]. Studies have shown that cytokines TNF-Į ,/-ȕDQG ,/-6
disrupt insulin signaling and lead to insulin resistance [58-63]. These cytokines in the
context of diabetes are secreted primarily by adipose tissue, either the adipocyte itself or
the infiltrating immune cells that accompany the tissue’s hypoxia [64]. Also, adipokines
such as leptin and adiponectin modulate energy homeostasis and insulin activity, and
6

their levels are also disrupted in obesity [65-67]. This may explain the association often
observed between obesity and diabetes. Adipose tissue then is a major player in diabetes
as it not only takes up free fatty acids and glucose, but also contributes to diabetes by
modulation of its endocrine function [64, 68, 69]. Adipose tissue is responsible for less
than 10% of whole body glucose uptake, yet genetic knockout of adipose tissue GLUT4
causes hyperinsulinemia and hyperglycemia characterized by liver and skeletal muscle
insulin resistance, exemplifying its role in diabetes etiology despite its minor contribution
to peripheral glucose uptake [70].
Similar to the pancreas, the liver expresses the insulin-independent glucose
transporter GLUT2 [6].

Once inside the hepatocytes, glucose is phosphorylated by

glucokinase (GCK), preventing its retrotransport back into the systemic circulation [71,
72].

Hepatic insulin signaling activates transcription of glucokinase [72, 73]. The

phosphorylated glucose molecule then undergoes several fates such as glycolysis, stored
as glycogen for later use, or can be used in the pentose phosphate pathway [6].
Moreover, in the fasted state when insulin levels are low, the liver undergoes
glycogenolysis and gluconeogenesis to supply glucose to the periphery [74, 75]. Insulin
signaling terminates these hepatic glucose production processes. Consequently, hepatic
insulin resistance causes decreased hepatic glucose flux due to decreased rate of
intracellular glucose phosphorylation, thereby permitting GLUT2-mediated retrotransport
of glucose back into the periphery [75]. The liver is also responsible for approximately
70% of insulin degradation [76-78]. In diabetic subjects, hepatic insulin clearance is
decreased anywhere from 20-65% [75, 79-81]. This presumably is protective against
hyperglycemia by mediating increased circulating insulin to be used by skeletal muscle
7

and adipose tissue to facilitate glucose uptake. However, this decreased hepatic insulin
clearance may precipitate peripheral insulin resistance and in turn produce a positive
feedback loop of hyperglycemia and insulin resistance. Further, it was observed that
visceral fat is more detrimental to insulin sensitivity than subcutaneous fat [82-84]. This
is interesting because glucoregulatory adipokines, cytokines and FFAs from visceral fat
drain to the portal vein directly to the liver mediating impaired hepatic glucose
homeostasis and insulin resistance [85].

Hepatic insulin resistance permits hepatic

glucose production in the presence of elevated insulin which further increases blood
sugar [86]. Together, the liver contributes to hyperglycemia both by decreasing glucose
uptake and storage, but also by dysregulated glucose excursion.
Skeletal muscle is a major site of glucose disposal, accounting for upwards of
90% of insulin-dependent peripheral blood glucose uptake, however approximately one
third of postprandial glucose is taken up by the liver [7, 87-90].
intracellular transport is dose-dependently mediated by insulin.

Skeletal muscle
Hyperinsulinemic

euglycemic clamp studies in both lean and obese type 2 diabetics revealed a greater than
50% decrease in whole body glucose disposal [87]. This reduction in insulin-stimulated
whole body glucose uptake was mirrored by a 50% increase in skeletal muscle EC50 for
insulin-mediated glucose uptake [87]. Additionally, not only were the skeletal muscles of
diabetic subjects resistant to insulin activity, a delay in the onset of insulin activity was
also observed [87, 90]. Intramyocellular FFAs and impaired mitochondrial ȕ-oxidation
are strongly associated with muscle insulin resistance, but it is difficult to establish a
causal relationship between the two [90-92]. Nonetheless, the result is impaired insulin
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signal transduction, impaired skeletal muscle metabolic flexibility, and consequently,
attenuated glucose uptake.
1.2 Developmental Origins of Health and Disease
1.2.1 Thrifty Phenotype. Barker and Hales conducted epidemiological studies in
the United Kingdom and observed that areas with the highest mortality rates were the
same areas with the highest infant mortality rates several decades earlier [93-95]. Upon
further investigation, it was discovered that not only did these geographical areas have
higher rates of mortality but also higher rates of metabolic disease as well [22, 96-98].
They then put forth the Thrifty Phenotype Hypothesis which explains that developmental
perturbations result in low birth weight offspring who have an increased risk of
developing cardiovascular and metabolic disease later in life. Low birth weight is a
phenotype resulting from intrauterine growth restriction which can have several causes
including maternal undernutrition and uteroplacental insufficiency.

Initial studies

investigated the role of maternal undernutrition on offspring body weight and agingassociated sequelae. In addition to low birth weight babies having increased risk of
developing metabolic disease, large babies do as well.

Figure 1.2.1 diagrams the

different intrauterine environments that precipitate metabolic disease that will be
discussed in more detail.
1.2.2 Maternal undernutrition. This hypothesis was evaluated in humans by
investigating outcomes of offspring who were in utero during times of famine. One of
the first and most famous studies is that of the Dutch famine. During the winter of 1944,
the Germans established a blockade of food to the Netherlands causing severe famine.
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Investigations of offspring who were in utero during this period revealed that children
were born with decreased placental and body weights although length and head
circumference were relatively less affected [99]. It is thought that reduced fetal nutrient
availability results in a brain-sparing effect [100, 101].

This describes vascular

development and subsequent nutrient redistribution to more important organs such as the
brain, heart and adrenal gland and the sequestration of nutrients away from visceral
organs of the liver, and kidneys [102-104]. As a result, growth-restricted infants often
have normal sized brains but underdeveloped visceral organs. Often the kidneys of small
infants have decreased nephron size and number, and moreover, the livers are smaller and
hypoperfused [105-107].
Ravelli et al. showed upon 2 hr glucose tolerance test that offspring who were in
utero during famine had increased glucose and insulin levels indicating impaired glucose
homeostasis and insulin resistance compared to those conceived after or born before the
famine [108]. It also appeared that those who were affected during the last trimester
exhibited the most marked derangements. Studies of Chinese Famine of 1959-1961
revealed elevated risk of impaired glucose homeostasis of those adults who were in utero
during famine [109, 110]. Those in utero during the most severe famine showed marked
impairments over those whose nutrient restriction was less severe. Additionally, the
researchers found those adults who were exposed to nutrient restriction during famine but
whose diets where rich later in life had the highest prevalence of glucose intolerance in
adulthood [109, 110]. Developmentally malnourished offspring upon later life nutrient
abundance demonstrated exacerbated glucose homeostatic maladaptation, illustrating
continued nutrient response postpartum.
10

1.2.3 Catch-up growth There is now a theory that low birth weight offspring,
when exposed to nutrient rich postnatal environment, display “catch-up” growth. Catchup growth is a phenomenon by which underweight infants experience rapid postnatal
growth eventually equaling and even surpassing the size of those born with normal birth
weight. Low birth weight offspring that would later develop type 2 diabetes were taller,
heavier, and had increased BMI by 7 years of age and during adolescents compared to
normal weight offspring [111-113]. A study of low birth weight South African children
revealed that those infants that underwent rapid weight gain during childhood exhibited
the most profound impairments in glucose tolerance [114, 115]. This same association
between catch-up growth and glucose intolerance was confirmed in Finnish children.
Those infants who were small for gestational age and experienced the most rapid increase
in BMI from 2 to 11 years of age were most likely to develop type 2 diabetes in
adulthood [114, 116]. Ong et al conducted a literature review and found that rapid
growth in infancy conferred a two to three fold increased risk of obesity with aging [117].
Not only is reduced birth weight and subsequent catch up growth associated with glucose
intolerance, but reduced birth weight is also associated with obesity in older individuals.
As mentioned in previous sections, the association between obesity and diabetes is well
established; therefore it is possible that the increased risk of diabetes in small babies may
be concomitant or secondary to the development of obesity. However the association
with impaired glucose disposal is generally greater than with obesity, indicating that
lifestyle probably plays more of a role in development of obesity than diabetes in the
context of developmental programming.
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1.2.4 Animal models: general

A wide variety of experimental techniques have

been employed to corroborate the human data linking low birth weight to metabolic
dysfunction in adults and also to elucidate the mechanisms involved. Intrauterine growth
restriction results in infants that are of decreased birth weight, or more precisely, small
for their gestational age. It is important to distinguish between the two as an infant may
be small because of premature birth and the ramifications may be different depending
upon prematurity or decreased fetal growth. Experimental techniques use maternal low
protein or low calorie diets, and uterine artery ligation to facilitate growth restriction.
Each of the experimental animal models of growth restriction exhibit decreased birth
weights compared to controls [118-122].

Although maternal undernutrition and

uteroplacental insufficiency have reduced birth weight offspring, the responses may be
quite different and consequently have varying mechanisms to disease progression [123].
1.2.5 Animal models of undernutrition Low protein (8% vs. 20%) isocaloric diets
utilized later in gestation result in growth restricted offspring, demonstrated by decreased
birth weights in rats despite comparable placental weights [121]. The brain sparing effect
is also observed in this model. Desai et al. showed offspring born to dams on low protein
diet had the smallest changes in absolute brain and lung weights, while reductions in
kidney, heart and thymus were proportional to the reduction in body weight, and the
pancreas, spleen, liver and skeletal muscle had reduced weights even when taken as a
proportion of body weight [124]. Regarding glucose homeostasis, both male and female
offspring born to protein restricted dams display glucose intolerance and insulin
resistance upon aging [125, 126]. Furthermore, pancreatic disturbances were observed
including decreased ȕ-cell mass, diminished islet proliferation and vascularization,
12

decreased islet insulin levels, and attenuated glucose-stimulated insulin secretion [119122, 127-130]. The fetal pancreas also showed increased islet apoptosis [131]. Caloric
restriction to at least 50% of ad libitum control animals also caused decreased birth
weight and age related impairments in glucose tolerance [120]. This model also exhibits
disturbances in the endocrine pancreas including decreased ȕ-cell mass and
differentiation [120, 128]. Abrogated insulin signaling mediated by decreased 3.&ȗ and
IRS-1 expression and increased serine phosphorylation of IRS-1 in skeletal muscle
indicates additional disruption in extrapancreatic tissues [132, 133].
As mentioned earlier, postnatal nutrition can further program the offspring toward
age-associated metabolic disease.

Cross fostering studies in which offspring from

malnourished dams were nursed to control dams, and vice-versa, support early postnatal
nutrition as important factors in later life disease susceptibility.

Growth-restricted

offspring nursed to low protein diet dams have growth rates that are comparable to
controls that persist as the offspring age, but the growth-restricted offspring weigh less
than controls at every time point [124]. The greatest pre-weaning growth was observed
in growth restricted pups that were fostered to control dams [124]. This intervention
group actually weighed the same as controls by weaning in a different study [134, 135]
Tissue specific effects of maternal undernutrition include adaptations of the liver
lobules which are larger in size yet fewer in number in growth-restricted animals [105].
Glucagon-stimulated glucose production was reduced, but insulin and glucagon together
caused an initial increase in glucose output and delayed glucose output suppression [105,
136]. Skeletal muscle glucose uptake diminishes with age, owing at least in part to
decreased expression of insulin signaling mediator PKC ȗ [133, 137]. The adipose tissue
13

from growth restricted animals resulted in age-dependent impairments in insulinstimulated glucose uptake and impaired inhibition of lipolysis resulting from attenuated
activation of insulin-stimulated PI3K activation [138]. Taken together, the endocrine
pancreas is disrupted with maternal undernutrition, but organs involved in glucose uptake
are also disrupted and exhibit insulin resistance upon aging.
1.2.6 Uteroplacental insufficiency Uteroplacental insufficiency refers to
incomplete attachment of the placenta to the uterus leading to diminished placenta
vascularization and subsequent reduction of placental and fetal blood flow.
Uteroplacental insufficiency thus results in placentas and fetuses that are hypoxic,
undernourished, and consequently growth restricted. It is the most common cause of
intrauterine growth restriction in humans, especially in developed countries [139].
Uteroplacental insufficiency may have several causes including hypertension and
maternal tobacco smoking [140].
Between 13 and 20% of American woman smoke cigarettes during pregnancy,
delivering one million infants exposed in utero to tobacco smoke [141]. Cigarette smoke
contains approximately 4800 compounds including aryl hydrocarbon receptor (AhR)
agonists in the class of polycyclic aryl hydrocarbons such as benzo(a)pyrene and
chlorinated dioxins and furans [141-144]. Maternal cigarette smoking is associated with
a myriad of developmental defects including uteroplacental insufficiency resulting in
reduced birth weight [145, 146]. It is also associated with increased risk of offspring
obesity development [147-150]. An investigation of American Indian children up to 3
years of age revealed the children whose mothers smoked at the initial prenatal visit were
twice as likely to be in the 85th percentile of weight despite having reduced birth weight.
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These 3 year old children born to mothers who smoked additionally had increased
weight-to-length ratio z-scores due to increased adiposity as compared to those toddlers
whose mothers were nonsmokers [147]. Data analysis from the 1958 British birth cohort
showed smoking during pregnancy resulted in reduced birth weights compared to
nonsmokers and that the odds ratio for obesity increased with age, and by 33 years of age
both men and women born to smokers had statistically significant odds ratio for diabetes
(1.56 and 1.41, respectively) [149]. Scientific data regarding maternal cigarette smoking
and subsequent diabetes risk in the context of developmental programming is lacking.
However, one study by Montgomery and Ekbom showed that maternal cigarette smoking
not only increased the risk of obesity with aging, but showed a strong association
between maternal smoking and later life diabetes prevalence by age 33 [150]. Moreover,
offspring born to mothers who smoked at least 10 cigarettes per day during pregnancy
were 4 times as likely to develop diabetes by age 33 than adults whose mothers did not
smoke during pregnancy [150].
1.2.7 Animal models of uteroplacental insufficiency Sequelae of uteroplacental
insufficiency is studied experimentally by employing uterine artery ligation. Uterine
artery ligation growth restricts the developing fetus by reducing blood flow to the
placenta [139, 151]. Consistent with uteroplacental insufficiency, the model exhibits
reduced ȕ-cell mass, impaired glucose homeostasis and decreased IGF-1 levels in growth
restricted offspring born to uterine artery ligated dams [130, 152]. Rat pups born to
ligated dams show global adiposity and insulin resistance as early as 10 weeks of age
which is in stark contrast to the experimentally undernourished model whose offspring
exhibit increased insulin sensitivity in early life and only exhibit insulin resistance and
15

diabetes upon significant aging [120, 123, 125, 126, 130, 153].

Oxidative

phosphorylation is impaired in the liver and skeletal muscle in offspring from ligated
dams, and insulin-mediated GLUT4-dependent glucose transport in muscle is attenuated
contributing to hyperglycemia [154, 155]. Pancreatic derangements may be mediated in
part by aberrant pancreatic and duodenal homeobox 1 (Pdx1) expression via epigenetic
modulations [118, 128, 156]. The Pdx1 gene plays pivotal roles in pancreatic
development [118, 119]. Three month old offspring from uterine artery ligated dams
displayed reductions in Pdx1 gene expression which was concomitant with an 80%
reduction in ȕ-cell mass. Interestingly, GLP-1 receptor agonist, Exendin-4, administered
at birth restored Pdx1 mRNA levels and ultimately ȕ-cell function [157, 158]. Exendin-4
further reduced hepatic oxidative stress and insulin resistance [157, 159].
1.2.8

Developmental

Programming associated

with

high

birth weight

Developmental programming of adult disease is not limited to those growth restricted
offspring; high birth weight offspring, too, have increased risk of later life metabolic
diseases [160-163]. There is a loss of maternal insulin sensitivity in late gestation in
normal pregnancies so as to increase insulin and nutrient availability for the developing
fetus, but this can lead to gestational diabetes when this insulin resistance becomes
pathologic. The Pima Indian population have increased incidence of diabetes [164-166].
Studies on this unique population revealed that both low birth weight and high birth
weight babies have increased risk of developing type 2 diabetes suggesting a U-shaped
relationship [167]. Pima Indian females whose mothers had gestational diabetes were
also more likely to develop diabetes [165]. Not only does diabetes lead to high birth
weight and metabolically perturbed offspring, but maternal obesity does as well. When a
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high fat obesogenic diet was given before mating, during gestation, and lactation, the
offspring were hyperphagic and had increased adiposity and insulin resistance [168].
Also, offspring of obese mothers have developmentally programmed nonalcoholic fatty
liver disease which can have additional metabolic sequelae including insulin resistance
[169]. Mestan et al showed correlations of maternal BMI and diabetes status (Type 2 or
gestational) were both positively correlated with large-for-gestational age offspring
phenotype, OR 2.64, 95% CI 1.31-6.20 and OR 5.58, 95% CI 2.06-15.13, respectively
[170]. Also the adipose tissue secreted cytokine RANTES in cord blood was found to be
correlated with large-for-gestational age and ponderal index in offspring [170]. Harder et
al conducted a meta-analysis of 14 studies investigating the association between birth
weight and adult Type 2 diabetes incidence and confirmed the U-shaped association
[171].
1.2.9 Conclusion Perturbations in the plastic periods of development during
gestation and infancy can have long lasting physiological effects which predispose one to
increased metabolic disease susceptibility later in life. There are varying causes of
reduced birth weight and similarly different yet converging paths to disease progression.
Fortunately, excellent experimental models of growth restriction and developmental
programming are available to help elucidate the mechanisms behind disease progression
in the two most prevalent causes on reduced birth weight. Uteroplacental insufficiency
can result from exposure to environmental toxins such as those found in cigarette smoke
and predispose offspring from maternal smokers to metabolic disorders later in life.
Similar to chemicals in cigarette smoke, polychlorinated biphenyls (PCBs) are also
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environmental toxins that activate the AhR, suggesting that they may also diminish
intrauterine growth and precipitate postnatal metabolic derangements.
1.3 Polychlorinated biphenyls
1.3.1 History of polychlorinated biphenyls

PCBs are a class of persistent

organochlorine pollutants that partition with lipids and biomagnify in the food chain
resulting in dietary exposure [172-174].

PCBs are dielectric molecules whose heat

resistant properties afforded many industrial uses including in electrical insulating fluids
and heat exchange fluids. They were used in electrical equipment such as transformers
and capacitors, fluorescent light ballasts, plastics, adhesives, paints, varnishes, and paper
[174, 175]. PCBs were manufactured in the United States under the trade name Aroclor.
In the 1970’s two accidental exposures in Southeast Asia revealed some potential health
hazards associated with dietary PCB exposure. These two incidents are the Yusho and
Yu-Cheng incidents of Japan and Taiwan, respectively, in which populations were
exposed to PCB via contaminated rice bran cooking oil [176-179]. Exposed subjects
presented with chloracne, hyperpigmentation, ocular lesions, neurological symptoms
including numbness, nausea and headaches, and digestive indications including vomiting
and diarrhea [180]. Consequently, the US Environmental Protection Agency (EPA)
banned production of PCBs in 1976 although use of the compounds was still permitted.
Investigations of PCB-associated health hazards in Western and European countries
confirm those of the Yusho and Yu-Cheng incidents, and additional health hazards
associated with PCB exposure have been observed including cancer, hypertension,
immune and thyroid dysfunction, asthma, obesity, diabetes and low birth weight [181183]. Over one billion pounds of PCBs were produced in the United States in the 50
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years of their production, and PCBs, particularly those with more chlorine substitutions,
resist biodegradation and therefore persist in the environment [173]. Although their
production has long ceased, currently over 450 million pounds have contaminated our
environment and PCBs are found in over 29% of hazardous waste sites in America and
have thus been categorized as ubiquitous environmental pollutants [173, 175, 184].
1.3.2 PCB Exposure PCBs enter the environment by improper disposal of PCB
waste and leakage of PCB containing fluids from electrical equipment.

They then

partition to the nonpolar components of the environment, particularly soil and sediment,
due to their hydrophobicity. When PCBs are volatilized they become airborne leading to
their detection in the atmosphere [185], and these characteristics give rise to their ability
to bioaccumulate in food chain [181]. Human exposure can be occupational for those
whose work involves PCB-containing materials, but for the majority of Americans, PCB
exposure is dietary coming primarily from animal based foods such as milk, beef and fish
[174]. Greatest dietary exposure comes from beef consumption although fatty fish such
as farm raised salmon have higher PCB concentrations on average [172, 174]. This
disparity is owed the large proportion of beef in the Western diet compared to fish.
Because fish have far greater levels of PCBs, some studies use sport fish consumption as
an estimate of exposure levels above background [186, 187].
PCBs have been detected in lipid rich tissues including adipose tissue, central
nervous system, liver, serum, placenta, cord blood and breast milk [186, 188, 189]. The
discovery of PCBs in placenta, cord blood and breast milk indicate exposure to these
pollutants as early as the time of embryonic implantation and throughout gestation,
lactation and the entire life course after weaning [188]. Owing to cessation of production
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and successful remediation procedures, environmental and body burdens of PCBs are
declining [190-192]. Fetal development is quite plastic and responsive to subtle changes
in its intrauterine and the early postnatal environment, as discussed regarding fetal
programming of metabolic disease [193, 194]. Also, several of the PCB-associated
health hazards were shown to have inverted U-shaped relationships suggesting that low
level exposures associated with declining environmental levels and body burdens may
actually be more detrimental than expected [195-198].
PCB exposure in the general population has been shown to be associated with low
birth weight in several epidemiological studies [182, 199, 200]. It then stands that in the
context of DOHaD, perinatal PCB exposure resulting in low birth weight may lead to
programming of metabolic diseases such as obesity and diabetes. Studies investigating
the association between PCBs and metabolic disease are done based upon postnatal PCB
exposure [183, 201-205]. Few studies have looked at perinatal exposure and subsequent
development of obesity with most prospective studies ending prior to adolescents and
having inconsistent results [206, 207]. Epidemiological studies investigating dietary
exposure and body burdens in adulthood show clear associations although causal
relationships are difficult to ascertain [208-210]. Regarding diabetes, even fewer studies
have investigated the association between early life pollutant exposure and diabetes risk
later in life. It does seem clear however that there is a correlation between diabetes risk
and PCB exposure as indicated by studies showing lack of association between obesity
and diabetes in subjects with lowest levels of PCBs and diabetes incidence increasing
with increasing plasma PCB concentrations [198, 204, 211]. Also, associations between
PCB exposure and diabetes are found predominantly in females, demonstrating sex20

specific effects of PCBs [212]. The contribution of PCBs to diabetes etiology is underinvestigated. Data regarding mechanisms of hyperglycemia in PCB-associated diabetes
are inconclusive. Some studies suggest the effect of PCBs on diabetes is not mediated
through insulin resistance but rather attenuated insulin secretion as evidenced by a
negative association between PCBs and homeostatic model assessment (HOMA)-ȕ (an
estimate of ȕ-cell function), but no association with HOMA-IR (measure of insulin
resistance based upon fasting glucose and insulin levels) [211-213].

Some studies

however, show positive associations with PCBs and insulin resistance [204]. Animal and
in vitro studies demonstrate PCB-induced insulin resistance mediated predominately by
adipose tissue [214, 215]. Although the association between PCB exposure and impaired
glucose homeostasis is rather evident, the mechanism remains unknown, as do the effects
of perinatal PCB exposure on glucose tolerance.
1.3.3 PCBs and AhR PCBs are composed chemically of two covalently bonded
benzene rings with at least one chlorine molecule substitution. Given that there are 10
different locations for chlorines to bind, there are 209 different combinations of chlorine
number and position; each different combination is called a congener [216]. There are
some congeners that are non-ortho or mono-ortho substituted that have coplanar
conformations while those having multiple ortho substituted chlorines display steric
hindrance and are referred to as non-coplanar.

Coplanar PCBs bind AhR whose

canonical ligand is 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin, also known as TCDD or simply
dioxin [216]. For this reason, coplanar PCBs are often referred to as dioxin-like PCBs.
The AhR is a ligand-activated DNA-binding transcription factor [217]. The receptor
resides in the cytosol interacting with heat shock protein (HSP) 90, prostaglandin E
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synthase 3 (p23), AhR interacting protein (AIP) [143, 218-221]. Upon ligand binding, a
conformational change uncovers the receptor’s nuclear localization signal causing its
nuclear translocation [222]. Once in the nucleus, the receptor dimerizes with the aryl
hydrocarbon nuclear receptor (ARNT) at which time it interacts with xenobiotic response
elements and regulates gene transcription [223, 224]. AhR facilitates transcription of
detoxifying enzymes such as cytochrome P450s (Cyp) 1a1, Cyp1b1 and phase II
enzymes, glucuronosyltransferases (UGTs) and glutathione-s-transferases (GSTs) [143].
Moreover, the receptor can interact with other transcription factors including nuclear
factor (erythroid-derived 2)-like 2 (Nrf2), HVWURJHQUHFHSWRUĮ ERĮ and RelA subunit of
nuclear factor kappa-light-chain-enhancer of activated B cells (Nf-țb), thereby
modulating their activities [225-230]. The detoxification process produces free radicals
which can cause oxidative stress and disruption or activation of redox responsive
signaling pathways [231]. These cellular AhR-dependent redox responses can contribute
to a myriad of pathological phenotypes leading to the aforementioned PCB-associated
diseases [232]. In fact, epidemiological studies find more positive correlations between
coplanar PCB exposure than with non-coplanar PCBs [212, 233-237].
1.4 Scope of Dissertation
1.4.1 Aims of dissertation The main purpose of this dissertation was to determine
whether PCB exposure during the critical windows of development, during gestation and
lactation, has an adverse effect on offspring body composition and glucose homeostasis.
Finally, I investigated changes in maternal hepatic gene expression during pregnancy and
in fetal and offspring livers perinatally exposed to PCB. These studies elucidate a role of
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early life environmental contaminant exposure in the subsequent development of obesity
and diabetes.
1.4.2 Rational

Epidemiological studies support an association between PCB

exposure metabolic disease. In support of the human studies, Baker et al, have recently
shown that direct exposure to coplanar PCBs cause adipose tissue inflammation and
insulin resistance leading to impaired glucose tolerance in male mice [214]. It is clear
however, that PCB exposure begins in utero and exposure this early in development can
have detrimental effects such as increased rates of malformations. This perturbation of
fetal development is evidenced also by decreased birth weights of offspring born to
mothers with increased exposure to PCBs. In the context of the DOHaD then, it is
reasonable to assume that these offspring will present with metabolic maladies of obesity
and diabetes.

Studies investigating prenatal PCB exposure on offspring body

composition reveal sex specific increases in adiposity and reduced lean mass in female
children 6.5 years of age, with boys of the same age being symmetrically smaller [238,
239].

At puberty, prenatal PCB exposure was associated with increased BMI in

Caucasian adolescents [238]. Further, the observed increase in body weight with prenatal
exposure holds true even when adjusted for postnatal exposure [239]. In vitro studies
support a role of PCB exposure in this phenotype as these pollutants inhibit skeletal
muscle differentiation and augment adipocyte differentiation [240, 241]. However, one
study investigated the effects of estimated prenatal PCB exposure on adult body weight
in females only, and it found no association between body weight and prenatal PCB
exposure [242].
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Epidemiological evidence shows positive associations between PCB body burden
and perturbed glucose homeostasis, but the contribution of perinatal PCB exposure to this
disease phenotype has not been investigated.

Langer et al, in their investigation

environmental pollution with impaired fasting glucose and thyroid dysfunction,
concluded that there is likely transgenerational transmission of these phenotypes
engendered by perinatal PCB and other pollutant exposure of the parent generation [187].
Despite the lack of evidence for a causal relationship between PCB exposure and
diabetes, the DOHaD provides rationale for PCB-induced disruption of glucose tolerance
in adults as sequelae to their disrupted fetal development.

Nonetheless, further

investigation into the role of perinatal pollutant exposure on offspring glucose tolerance
is clearly warranted. Finally, the livers primary function is macronutrient homeostasis
and xenobiotic detoxification. The effects of xenobiotic detoxification on hepatic gene
expression has been studied, but not during pregnancy and fetal development, and not
using PCBs. Moreover, a role of AhR in liver organogenesis has been identified,
indicating temporal and spatial opportunity for AhR agonists to exert effects during
hepatic development and maturation that may have long-term consequences.
1.4.3 Hypothesis and specific aims Hypothesis: Maternal coplanar PCB exposure
during pregnancy and nursing will result in reduced birth weight offspring that will
develop obesity and glucose intolerance with aging. Figure 1.4.1 diagrams the overall
hypothesis and experimental approach to the dissertation. Aim 1: To test the hypothesis
that perinatal PCB exposure will cause reduced birth weight and disease-associated
modulation of body composition in aged offspring. Aim 2: To test the hypothesis that
perinatal PCB exposure will impair glucose tolerance. Aim 3: To investigate alterations
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in liver gene expression pattern upon PCB exposure during pregnancy and fetal
development.
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Causes

Animal
Model

In Utero

Outcome

Maternal Undernutrition
•Famine
•Eating disorders

Placental Insufficiency
• Hypertension
•Cigarette smoking

Fetal Overnurtition
•Western diet
•Maternal diabetes

Maternal low protein or
low calorie diets

Uterine artery ligation

Maternal high fat or high
calorie diets

•Normal placental function
•IUGR due to lack of
building blocks

•Small and dysfunctional
placenta
•IUGR due to decreased
blood flow

•Large functional placenta
•Fetal overgrowth due to
increased building blocks
and insulin

Increased Risk of Obesity and Diabetes with Ageing

Figure 1.2.1 Overview of developmental origins of metabolic disease.

Maternal

undernutrition and placental insufficiency both cause intrauterine growth restriction
(IUGR) although by different mechanism. Fetal overnutrition can result in unusually
large fetuses. Interestingly, however, these various fetal milieus precipitate a convergent
phenotype of increased obesity and diabetes risk.

Fortunately, experimental animal

models have been developed to elucidate the mechanisms involved.
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PCB/Vehicle

Periconception

Lactation

Gestation

Aim 3
Cl

Cl

Cl
Cl

Hepatic Gene Expression
•Non-pregnant, Dam and E18 pups
•Genes of interest

Aging

•Macronutrient metabolism
•Xenobiotic detoxification
•Oxidative and ER stress

Cl

Offspring

In Utero Perturbations

•PCB 126
•3,3’,4,4’,5-pentachlorobiphenyl
•Aryl hydrocarbon receptor agonist
•Toxic equivalency factor = 0.1

Aims 1 & 3 •Weigh pups and placentas
Aim 1

Body Composition Analysis
•Echo MRI

Aim 2

Glucose Homeostasis
•Glucose Tolerance Tests
•Oral and IP
•Insulin Tolerance Test

Figure 1.4.1 Specific Aims Diagram. Female CD-1 mice were exposed biweekly to
safflower oil vehicle or PCB 126 via oral gavage such that mice exposure occurred near
the time of conception, and once also during gestation and lactation. One cohort of mice
was allowed to deliver their litters and nurse. These offspring were evaluated for body
composition and glucose tolerance in Aims 1 and 2, respectively. A separate cohort was
sacrificed at embryonic day 18 (E18) and pups and placentas were weighed to determine
in utero developmental blight. Absolute messenger RNA quantitation of livers from
fetuses, dams, and non-impregnated females were performed using NanoString nCounter
Technology in Aim 3.
Copyright © Cetewayo Saif Rashid 2013
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CHAPTER 2
PERINATAL POLYCHLORINATED BIPHENYL 126 EXPOSURE ALTERS
OFFSPRING BODY COMPOSITION
2.1 Abstract
Polychlorinated biphenyls (PCBs) are ubiquitous environmental contaminants whose
exposure levels are associated with various health hazards. We hypothesized that in
utero and lactational exposure to PCBs can cause changes in body composition and
obesity in a mouse model.

Pregnant mice were exposed biweekly to increasing

concentrations of PCB 126 via oral gavage. Maternal PCB exposure did not result in
heavier offspring, however, dose-dependent and sex specific changes in body
composition were observed. Female offspring displayed the most susceptibility to PCBinduced alterations in body composition, having less percent lean body mass and
increased adiposity compared to females born to control dams, and these effects were
largely dose-dependent. In contrast to females, and independent of the exposure level of
PCB 126, male offspring had reduced lean body mass but no change in fat mass
compared to males born to control dams. In conclusion, perinatal PCB 126 exposure did
not affect body weight, but rather modulated body composition in a dose-dependent and
gender-specific manner.
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2.2 Introduction
Polychlorinated biphenyls (PCBs) were produced in the United States (US) until their
ban in 1976 upon realization of their many hazards to human health [174]. Although
production of PCBs has long ceased, environmental contamination remains, and PCBs
are found in over 29% of hazardous waste sites in the US [174]. Primary sources of PCB
exposure for the general population include contact with ground water or contaminated
soil due to inappropriate disposal of materials containing PCBs, food contamination from
food storage in silos with PCB-coated interiors, and consumption of fish from
contaminated waterways [174]. Additionally, PCBs resist biodegradation, are lipophilic,
and consequently bioaccumulate in the environment and in the food chain, thus exposing
millions of Americans to these toxic compounds [173].
PCBs are ubiquitous and persistent environmental pollutants whose presence in utero
perturbs fetal development. The developmental origins of health and disease hypothesis,
derived from the thrifty phenotype hypothesis put forth by Barker and Hales in 1992,
postulates that low birth weight offspring can result from insufficient nutrition in the
intrauterine environment, leading to metabolic and other health derangements later in life
[22, 243-247]. Animal models of low birth weight employing uterine artery ligation and
protein or calorie restriction all show catch up growth and subsequent obesity with aging.
In fact, maternal serum PCB levels in humans negatively correlate with infant birth
weight and weight for gestational age [182, 199, 200, 248-251].

A meta-analysis

comparing prenatal PCB exposure and birth weight effects across 12 European birth
cohorts found a significant negative correlation between cord blood PCB levels and birth
weight [182]. Other studies confirmed that low-level PCB exposure during the perinatal
29

period can significantly affect fetal growth and birth weight [199, 248-253]. In contrast,
other studies found minimal or no correlation between perinatal PCBs and birth weight
[254, 255].
Prospective studies investigating the effects of PCB exposure on body weight are
incongruent, to say the least. Tang-Peronard et al. review of the literature in 2011 cited
eight prospective studies looking at the effects of prenatal PCB exposure on body weight;
3 found positive associations with body weight, while another 3 found negative
associations and the remaining 2 found no significant relationship between the two
variables [200, 206, 208, 238, 242, 250, 256-258].

Further, non-monotonic dose-

dependent relationships were observed [208]. The 2 prospective studies found positive
associations with low PCB exposure (<1.0 ng/mg serum lipid) and body weight while
high exposure (>4 ng/mg serum lipid) was correlated with decreased body weight [202,
[200, 256, 257, 259]. Maternal serum levels between these amounts were divergent with
some showing positive, negative and nonsignificant associations [206, 238, 242, 250,
258]. These effects were divergent regarding gender such that prenatal PCB exposure
predominantly affected females in the nonmonotonic manner, while the male offspring
were unaffected [208, 239]. These prospective studies, however, are limited in that only
Karmaus et al investigated maternal PCB exposure on adult offspring which were of the
female sex, and they found no association with maternal PCB exposure and BMI [242].
This is in contrast to cross sectional and case control studies that find significant
associations with obesity and serum concentrations of PCBs in males [121, 208, 209,
260-263]. The lack of effect of prenatal PCB exposure in young males, but not females,
but with effects observed in cross sectional studies is intriguing. Cross sectional studies
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cannot determine causality, therefore the possibility of PCB induced developmental
programming of obesity in males cannot be ruled out. Nonetheless, these studies indicate
sex specific effects of PCB exposure on obesity.
Experimental studies utilizing animal models and in vitro techniques further
demonstrate a role of PCB in adipose tissue development. Specifically, Arsenescu et al
showed that dioxin-like PCB 77 or TCDD itself at low doses increased adipocyte
differentiation in 3T3L1 preadipocytes whereas higher concentrations inhibited adipocyte
differentiation. Additionally, in wildtype but not aryl hydrocarbon deficient mice, direct
exposure of PCB 77 increased weight body weight mice [241]. These data provide a
mechanism by which developmental exposure to dioxin-like pollutants can affect
adipocyte differentiation in nonmonotonic dose-dependent manners observed in human
studies.
Moreover, the decreased body weight observed primarily in females upon higher
exposure levels can be concomitant with hypotonia and diminished physical activity in
preschool aged children, but these effects are short-lived as they are not observed into
puberty [258, 264]. These effects were thought to be due to lactational exposure rather
than exposure in utero suggesting that heightened perinatal exposure, due in part to breast
milk contamination, decreases body weight [258, 264]. The effect of perinatal PCB
exposure on offspring lean mass is not well established, therefore using only BMI and
body weight as marker of obesity is unavailing because they do not take into account the
possible effects of PCB exposure on lean mass. Coletti et al found that Aroclor mixtures
of PCBs dose-dependently diminish skeletal muscle differentiation in primary fetal
myoblasts and in a myogenic cell line without affecting viability or proliferation,
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supporting a role of PCB exposure on the disruption of skeletal muscle development in
utero [240].
Evidence suggests that exposure to environmental pollutants can contribute to the
pathology of obesity, and recent human studies support our hypothesis that perinatal
exposure to PCBs is associated with overweight offspring [182, 239]. Thus, the purpose
of this study was to investigate gender-specific differences in body composition of both
young and aged offspring born to PCB-exposed dams.
2.3 Materials and Methods
2.3.1 Animals and diets: At 2 months of age, female ICR mice were bred and
subsequently produced one litter at Taconic prior to their purchase and shipment to the
University of Kentucky at roughly 4 months of age. The following studies were carried
out at the University of Kentucky according to an approved Institutional Animal Care and
Use Committee protocol. Females were housed 4 mice per cage for a 2 week acclimation
period prior to mating. Female mice were fed a semi-purified low fat diet containing
10% kcal from fat (Research Diets D12450B) ad libitum for the duration of the study.
Male ICR sires (Taconic) were fed standard chow (Teklad Global 18% Protein Rodent
Diet #2018) during a 7 day acclimation period then mated to dams, 1 sire per 2 dams. In
order to equilibrate nutrient availability, litters were culled to 6 pups on postnatal day 3.
Pups from litters with more than 6 pups that were born on the same day were crossfostered to dams nursing less than 6 pups. Body weight and maternal food intake were
monitored weekly throughout weaning. Pups were weaned on postnatal day (PND) 21
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onto standard chow, and male and female offspring were housed 3 and 5 mice per cage,
respectively.
2.3.2 PCB Exposure: 3,3’,4,4’,5-pentachlorobiphenyl (PCB 126) was purchased from
AccuStandard (C-126N New Haven, CT). PCB 126 was dissolved in tocopherol stripped
safflower oil (Dyets # 403952 Bethlehem, PA). Female mice were orally gavaged with 0,
0.5 or 1.0 μmole of PCB 126 per kg body weight at a frequency of once per 14 days. The
frequency was such that the dams were exposed to PCB 48 hours prior to mating, once
during gestation, and once during lactation (Figure 1).
2.3.3 Body composition: At 7 weeks, 6 months and 9 months of age, nuclear magnetic
resonance (EchoMRI; EchoMedical Systems; Houston, TX) was employed to quantify fat
mass and lean body mass in both female and male offspring born to vehicle or PCB
exposed dams. Although many tissues contribute to the lean mass output, there are
undetectable components such as bone mineral content, hair, and claws which contribute
to void mass. Body composition measurements in Tables 2 - 7 include data from only
one female and one male offspring per litter, respectively. Body weight was measured
just prior to body composition analysis.
2.3.4 Statistics:

Overall differences in maternal body weight were determined by

repeated measures ANOVA using IBM SPSS statistics 20 software. One-way ANOVA
was used to make comparisons between groups for the remaining comparisons in Tables
1-3. Fisher LSD Method was used for post hoc comparisons. Upon the event of a failed
Shapiro-Wilk normality test, data were transformed using natural log. Kruskal-Wallis
ANOVA on Ranks was used when the data failed the equal variance test or failed
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normality following transformation. These analyses were completed using SigmaPlot
12.0 software.
2.4 Results
2.4.1 Maternal effects of biweekly PCB 126 exposure and pup body weight: Figure 1A
illustrates the perinatal exposure model used in the current study. Exposure at
concentrations of 0.5 and 1 μmole PCB per kg body weight did not affect pregnancy rate
(Table 2.1) or maternal body weight (Figure 2.1B) when compared to vehicle controls.
In order to promote successful rearing, litters were not disturbed until postnatal day 3, at
which time pups per litter were enumerated. The 1 μmole/kg dose led to significantly
decreased litter size compared to controls. There was no significant difference in pup
body weight on PND 3 although there was a trend toward decreased body weights in
male offspring maternally exposed to PCB 126 compared to those from control dams at
postnatal day 21 (p=0.083) (Table 2.1).
2.4.2 Body composition analysis: At 7 weeks, 6 months and 9 months of age, body
composition analyses were conducted using EchoMRI, and the data are presented in
Tables 2.2 – 2.7. Perinatal PCB exposure resulted in gender specific differences in body
composition.

Females born to PCB exposed dams had similar body weights, yet

displayed significantly increased adiposity compared to females born to vehicle treated
dams. Females perinatally exposed to 0.5 μmole/kg and 1 μmole/kg PCB 126 showed a
dose-dependent 8.2% and 11.5% increase in percent body fat compared to females born
to control dams (p=0.044 and p<0.001, respectively). The largest effect was seen in the
high exposure group as these offspring additionally displayed significantly elevated fat
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mass and a nearly 4% reduction in percent lean body mass (p=0.004 and p=0.005,
respectively). Despite a lack of difference in body weight upon perinatal PCB 126
exposure, there were significant alterations in body composition at this early time point.
While prospective epidemiological studies show an increase in body weight as
representative of increased fatness in female offspring, we too demonstrated an increase
in fatness. The decrease in lean mass contribute to comparable body weights despite
increased grams of fat mass and increased % fat mass in these females. With aging, these
PCB-induced effects are attenuated such that body composition is comparable in females
perinatally exposed to PCB and control animals at 6 and 9 months of age, Tables 2.4 and
2.6, respectively.
For male offspring at 7 weeks of age, there was no significant effect of perinatal PCB
exposure on body weight (p=0.368). In contrast to that which was observed in females,
male offspring born to PCB exposed dams showed no difference in adiposity taken as
either weight of fat mass or when expressed as a percentage of body weight (p=0.876 and
p=0.536, respectively). There was, however, a significant reduction in grams of lean
mass between the groups; specifically, males perinatally exposed to 0.5 μmole/kg and 1
μmole/kg PCB 126 showed significant reductions in lean mass (8.3% and 9.9%,
respectively).

However, there was no significant difference in percent lean mass

(p=0.268). Perinatally exposed males at 6 months of age had a dose-dependent decrease
in body weight compared to controls, most of which is attributed to reductions in grams
of lean mass of PCB-exposed mice (Table 2.5). Specifically, these males born to dams
administered 0.5 μmole/kg PCB 126 displayed 10.5 and 10.4 percent reductions in body
weight and lean mass, respectively, while males born to dams given 1 μmole/kg PCB 126
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exhibited 13.1 and 15.1 percent reductions in body weight and lean mass, respectively.
This diminished lean mass accounted for 63 and 74% of the reduced lean mass in the 0.5
and 1 μmole/kg exposed males respectively. These trends persisted with further aging
such that at 9 months of age there was again dose-dependent reductions in lean mass in
PCB exposed males although the body weight difference was no longer statistically
significant (p=0.058) (Table 2.7). The reduction in lean mass is dose-dependently, 11.2%
and 17% for the two PCB exposed groups, respectively. Interestingly, the 0.5 μmole/kg
decrease in lean mass is actually greater than the reduction in body weight for that group,
an effect made possible by a slight increase in fat mass.
2.5 Discussion
The current study focused on the effects of perinatal PCB exposure on genderspecific body composition changes in the offspring. Because many studied causes of low
birth weight are due to intrauterine growth restriction resulting from maternal
undernutrition, it is important to note that maternal body weight was not affected by PCB
exposure [22, 112, 265, 266]. It is uncertain whether or not the congener dosing and
frequency used in this experiment caused low birth weight because initial pup weights
were not measured until PND 3 instead of PND 0 so as to promote successful rearing.
Nonetheless, there was no difference in body weight between pups born to control or
PCB exposed dams at the first measurement of offspring body weight at PND 3. In fact,
pup body weights were comparable throughout weaning. When mice were sexed at
postnatal day 14, there was also no difference in body weight between treatment groups
within each gender. In the event that low birth weight had occurred, it is unlikely that
catch up growth would have occurred 3 days post-partum [267, 268]. Further, in Aim 3
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we measured fetal weights at day 18 of gestation in vehicle and PCB exposed dams and
no significant differences in fetal weights were noted.
Possible toxicity of our dosing regimen was evidenced by the reduced litter size in the
1 μmole/kg PCB 126 dose compared to control. The observed reduction in litter size is a
likely consequence of poor rearing because unpublished data from our laboratory
revealed no differences in fetal number at embryonic day 18 when dams were
administered 1 μmole/kg PCB 126 as in the current exposure model (see Aim 3). Studies
in humans have shown conflicting effects of maternal PCB exposure on fecundity, and
specifically time to pregnancy [269-274].
In the present study, at 7 weeks of age, there was still no effect of perinatal PCB
exposure on offspring body weight in these mice. Hertz-Picciotto et al. showed that in
humans, in utero PCB exposure of males was associated with low birth weight and body
weight for gestational age in boys, while in girls, in utero exposure was associated with
shorter gestation [200]. In the same study, at five years of age, prenatal PCB exposure
was associated with increased growth in girls but not boys [200]. Additionally, a recent
prospective study conducted in humans revealed a significant positive correlation
between cord blood concentrations of PCBs and overweight in females 6.5 years of age
[239]. The males in that study did not exhibit such an association, although there was a
trend toward a negative correlation between moderate prenatal PCB exposure and
overweight. Our current experiment shows similar trends (Tables 2.2 and 2.3), such that
perhaps with an increased sample size, we too would have observed statistically
significant dose and gender-specific effects of maternal PCB exposure on body weight.
Interestingly, when Valvi et al. adjusted for birth weight, the association between
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overweight and PCBs strengthened, and the findings still held true even when only
normal birth weight offspring were included, suggesting that prenatal PCB exposure in
the absence of low birth weight may still contribute to the overweight phenotype [239].
Although it was assumed that increased weight at 6.5 years of age was caused by
increased adiposity, confirmation was not provided [239].
In the current experiment, body composition analyses showed female offspring born
to PCB exposed dams had increased adiposity as well as reduced lean body mass
compared to offspring from vehicle treated dams despite comparable body weights. The
observed adiposity is consistent with published data in mice which demonstrated
coplanar PCB 77 augmented body weight gain, adiposity, and adipocyte differentiation
[241]. There are previous reports in humans of PCB levels correlating with decreased
muscle tone in females and from these studies, it appears evident hypotonia occurs
preferentially in females [275-277]. Also, there is evidence that while in utero exposure
best correlates with later life neurocognitive impairments, it is lactational exposure that
best associates with hypotonia [258, 275, 276]. In the present study, male offspring
displayed no such increased adiposity. In contrast to females, male offspring born to
dams exposed to 1 μmole PCB 126 /kg body weight had decreased lean body mass
compared to control males (Table 2.3).
It is interesting that with aging, the effects of PCB exposure on female offspring are
attenuated. This could be indicative of a direct exposure effect in the females because
without additional dietary exposure to PCBs the body burden would decrease mirroring
the decreased difference in body composition observed between PCB exposed females
and controls. The body composition effects in the male offspring persisted. Intriguingly,
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there was no alteration in adiposity demonstrated at any time during the course of the
study which is in agreement with prospective studies [200, 206, 208, 238, 239, 250, 258].
The majority of cross sectional studies found an increase in body weight in males [121,
260, 262]. The divergence between these cross-sectional studies and the present one may
be attributed to a myriad of factors including timing and duration of exposure, nutritional
status and of course species.
Timing of maternal exposure may be important in PCB-induced abnormal
development, and consequently future studies will include cross-fostering of pups born to
PCB-treated dams with those of vehicle-treated dams to further clarify compositional
changes induced by exposure to PCB. Cross-fostering will allow us to establish whether
PCB exposure in utero or during lactation precipitates these aberrant changes in body
composition. If lactational exposure is deemed most detrimental, then perhaps steps could
be taken to minimize lactational exposure such as formula feeding.
Results from the presented experiment are similar to findings in humans, thus
supporting current and future use of this exposure model to assess effects of maternal
PCB exposure on altered body composition in the offspring. In addition, this model can
be utilized to determine mechanisms causing or regulating long-term outcomes in body
composition.

Future studies will investigate impacts these maladaptations of body

composition will have on metabolic disease risks, specifically glucose tolerance.
Because skeletal muscle and adipose tissue are key components of glucose disposal, one
would suspect differences in body composition of female mice exposed to PCBs may
predispose their offspring to impaired glucose tolerance at a young age and perhaps the
male offspring too will display impairments in glucose tolerance as a result of their
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decreased lean mass. My data clearly demonstrate that perinatal PCB exposure impacts
body composition in young females and males of all ages, increasing adiposity and
reducing lean body mass, respectively.

Later life implications of such early PCB

exposure and the development of obesity-associated pathologies remain uncertain.
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7.923*
(0.560)
0.043

13/15

-

1

P

5.344

0.865

11.429

0.615

(0.473)

10.901

(0.308)

11.012
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0.083

(0.724)

15.276

(0.396)

15.866

(0.490)
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(15.510)

15.510
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16.242
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Abbreviations: PCB : polychlorinated biphenyl, PND : Postnatal day, SEM : standard error of the mean
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11.031
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11.299

Female
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2.527
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9.133

15/15

0.5

5.473
(0.164)

2.446
( 0.0967)

10.462

13/15

0

PND 7

PND 3

Mean Pup Weight (g)
(SEM)

( 0.781)

#
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PCB 126
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litter on
PND 3

Table 2.1Ň/LWWHUQXPEHUVL]HDQGPHDQSXSERG\ZHLJKW

Table 2.2Ň)HPDOH%RG\&RPSRVLWLRQat 7 Weeks of Age

Dose of PCB 126
(μmole/kg)

0
(n=12)

Mean
(SEM)
0.5
(n=15)

Body Weight (g)

29.33
(0.80)

30.43
(0.71)

31.56
(1.41)

0.298

Fat Mass (g)

5.76
(0.52)

6.91
(0.45)

8.57**
(0.94)

0.015

Fat (%)

19.37
(1.21)

22.45*
(0.92)

26.54**
(1.93)

0.003

Lean Mass (g)

20.52
(0.39)

20.69
(0.31)

20.33
(0.59)

0.830

Lean (%)

70.23
(1.09)

68.23
(0.81)

65.00**
(1.70)

0.017

1
(n=10)

P

*,** Significantly different from 0 μmole/kg control, p<0.05 and p<0.01, respectively.
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Table 2.3Ň0DOH%RG\&RPSRVLWLRQat 7 Weeks of Age

Dose of PCB 126
(μmole/kg)

Mean
(SEM)
0
0.5
1
(n=10) (n=11) (n=13)

P

Body Weight (g)

39.58
(1.64)

37.69
(0.91)

36.82
(1.45)

0.368

Fat Mass (g)

6.72
(1.05)

7.20
(0.73)

6.76
(0.42)

0.876

Fat (%)

16.35
(1.91)

18.80
(1.61)

18.28
(0.77)

0.476

Lean Mass (g)

28.51
(0.64)

26.15*
(0.39)

25.68**
(0.91)

0.024

Lean (%)

72.59
(1.83)

69.66
(1.49)

69.96
(0.82)

0.286

*, ** significantly different from control, p<0.05 and p<0.01, respectively.
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Table 2.4Ň)HPDOH%RG\&RPSRVLWLRQ at 6 months of Age

Dose of PCB 126
(μmole/kg)

0
(n=12)

Mean
(SEM)
0.5
(n=15)

Body Weight (g)

45.83
(2.26)

46.39
(2.14)

47.01
(2.25)

0.938

Fat Mass (g)

16.33
(1.80)

17.51
(1.74)

18.82
(1.53)

0.629

Fat (%)

34.49
(2.42)

36.33
(2.42)

39.46
(1.54)

0.365

Lean Mass (g)

25.23
(0.59)

24.55
(0.51)

24.18
(0.83)

0.529

Lean (%)

55.97
(1.91)

54.05
(1.96)

51.87
(1.19)

0.313

1
(n=11)

P
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Table 2.5Ň0DOH%RG\&RPSRVLWLRQat 6 months of Age

Dose of PCB 126
(μmole/kg)

Mean
(SEM)
0
0.5
1
(n=10) (n=13) (n=12)

P

Body Weight (g)

54.55
(1.69)

48.80*
(1.67)

47.39*
(2.34)

0.043

Fat Mass (g)

13.49
(0.89)

11.72
(1.57)

11.97
(1.34)

0.724

Fat (%)

24.18
(1.26)

23.16
(2.56)

24.87
(2.42)

0.896

Lean Mass (g)

35.03
(0.92)

31.39*
(0.73)

29.73**
(1.45)

0.007

Lean (%)

64.74
(1.30)

65.01
(2.17)

63.11
(2.00)

0.835

*, ** significantly different from control, p<0.05 and p<0.01, respectively.
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Table 2.6Ň)HPDOH%RG\&RPSRVLWLRQ at 9 months of Age

Dose of PCB 126
(μmole/kg)

0
(n=12)

Mean
(SEM)
0.5
(n=15)

Body Weight (g)

52.43
(1.84)

51.91
(2.64)

52.93
(2.74)

0.960

Fat Mass (g)

22.69
(1.50)

23.03
(2.17)

24.35
(1.69)

0.723

Fat (%)

42.78
(1.43)

42.48
(2.83)

45.74
(1.19)

0.334

Lean Mass (g)

26.24
(0.41)

25.55
(0.59)

25.27
(1.13)

0.944

Lean (%)

50.48
(1.27)

50.73
(2.29)

47.92
(0.84)

0.414
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1
(n=9)

P

Table 2.7Ň0DOH%RG\&RPSRVLWLRQat 9 months of Age

Dose of PCB 126
(μmole/kg)

Mean
(SEM)
0
0.5
1
(n=10) (n=12) (n=10)

P

Body Weight (g)

55.50
(2.02)

51.78
(1.72)

47.96
(2.47)

0.058

Fat Mass (g)

13.44
(1.43)

14.22
(1.39)

13.03
(1.74)

0.848

Fat (%)

23.67
(2.06)

26.85
(2.10)

26.83
(3.28)

0.601

Lean Mass (g)

36.24
(0.83)

32.18*
(0.62)

30.08**
(1.85)

0.004

Lean (%)

65.74
(1.66)

62.68
(1.73)

62.91
(2.56)

0.459

*, ** significantly different from control, p<0.05 and p<0.01, respectively.
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Figure 2.1 Maternal PCB 126 Exposure and Body Weight. A) Schematic diagram of
exposure model. Dams were administered 0, 0.5 or 1.0 μmole of PCB 126 per kg body
weight via oral gavage every 14 days beginning 48 hours prior to mating until
approximately postnatal day 7, for a total of 3 exposures. Females were allowed to mate
for 7 days; therefore, the exact developmental day of exposure was unknown. Day 0
signifies date of birth. Litters were delivered over a span of 7 days. Mice were weaned
on postnatal day 21. B) Maternal body weight. Dam body weights were taken weekly
prior to mating. During mating and gestation, dam body weights were taken daily until
birth and again beginning on postnatal day 3 until weaning. There were no differences in
maternal body weight between treatment groups (p=0.459).
Copyright © Cetewayo Saif Rashid 2013
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CHAPTER 3
SEX-SPECIFIC IMPAIRMENTS OF GLUCOSE TOLERANCE AS A
CONSEQUENCE OF PERINATAL POLYCHLORINATED BIPHENYL
EXPOSURE
3.1 Abstract
Diabetes rates are increasing alarmingly. There is experimental evidence that
environmental pollutants may be involved in diabetes etiology and there are plastic
developmental periods in which xenobiotic exposure can have long term consequences
on health. The present study investigated the effects of maternal polychlorinated biphenyl
(PCB) exposure on offspring glucose homeostasis.

Female CD-1 mice were orally

gavaged biweekly with vehicle (safflower oil) or 1 μmole/kg coplanar PCB 126
beginning 48 hours prior to mating until weaning. Oral glucose tolerance tests were
performed at 7 weeks, 6 and 9 months of age. Male offspring displayed impaired glucose
tolerance at only 7 weeks of age while female offspring exhibited impaired glucose
tolerance at 6 and 9 months of age. Interestingly, glucose intolerance in female offspring
were dependent upon fasting time and route of glucose administration as prolonged
fasting and intraperitoneal glucose administration resulted in glucose disposal rates
comparable to control females. Insulin tolerance test was performed at 8 months of age
and neither males nor females perinatally exposed to PCB 126 had attenuated insulin
sensitivity. These data indicate sex-specific roles of perinatal PCB exposure on glucose
homeostasis impairment. Further studies are needed to elucidate mechanisms involved in
maternal PCB exposure-induced hyperglycemia and should investigate splanchnic
disruptions that may be involved.
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3.2 Introduction
Polychlorinated biphenyls (PCBs) are a class of persistent organochlorine
pollutants that partition with lipids and biomagnify in the food chain resulting in dietary
exposure [173, 174, 278]. Since production of PCBs was banned in 1976 and remediation
has been established, their levels in the environment are decreasing, and consequently,
dietary exposure and body burdens are also decreasing. Paradoxically, the incidence of
diabetes has increased alarmingly over the past several decades and while advancements
in understanding the mechanisms of hyperglycemia have been made, diabetes etiology
remains elusive [181, 232]. Associations of diabetes and environmental pollutants in the
form of organochlorines have recently been uncovered, but the findings across studies
have been inconsistent.
Cross-Sectional studies of National Health and Nutrition Examination Survey
(NHANES) data show clear associations between Type 2 diabetes mellitus (T2DM) and
serum PCB levels [260, 279-281]. Everette et al found that PCB 126 was associated with
diagnosed or undiagnosed diabetes, and also associated with prediabetes with HbA1c
5.9% - 6.4% [260, 279]. Turyk et al evaluated this association in Great Lakes fish
consumers and found that dioxin-like PCBs but not total PCBs was associated with
diabetes, but this finding did not hold true when adjusted for another organochlorine p,p’diphenyl dichloroethene (DDE) [93].

Transnational studies confirm this positive

association between PCBs, particularly dioxin-like PCBs, and diabetes [282-286]. These
observed associations may be explained by an attenuation of xenobiotic clearance in
diabetics, therefore one cannot conclude that PCB exposure is involved in diabetes
etiology. Prospective studies are of better use in elucidating causality. Prospective
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studies reveal increased risk of diabetes upon PCB exposure primarily in women [202,
287, 288]. However, two prospective case control studies failed to find an association
between diabetes incidence and PCB levels; one was conducted in middle-aged Swedish
women using only PCB 153 as an indicator of PCB exposure and the other was
conducted from the Coronary Artery Risk Development in Young Adults (CARDIA)
cohort study [259, 289]. Taken together, epidemiological studies are suggestive of a role
of PCB exposure in the etiology of diabetes, particularly in women.
Transplacental transport of PCBs has been reported, and PCBs have been found in
cord blood and breast milk indicating early life exposure beginning in utero [182] [188].
In an attempt to explain the paradox of decreasing exposure and increasing diabetes
incidence, Lee at al hypothesized that low level exposure in utero may have pronounced
epigenetic effects mediating diabetes susceptibility [261]. In fact, PCB exposure has
been shown to be associated with low birth weight in some studies, and it is now well
established that low birth weight offspring have an increased risk of developing diabetes
later in life [182, 184, 200, 230, 248, 249, 290]. Despite the growing evidence of the
importance of PCB exposure on glucose homeostasis, there are no reported investigations
of perinatally exposed offspring and later life glucose tolerance.
In the present study, we employed a rodent model of perinatal PCB exposure
which mimics body composition effects in young humans perinatally exposed to PCBs
[291]. Previously, I have shown that mice born to dams exposed to a biweekly regimen
of 1 μmole/kg PCB 126 displayed increased adiposity and decreased lean mass in female
and male offspring, respectively. These alterations in body composition could have an
impact of glucose tolerance, as increased adiposity may cause insulin resistance and
51

subsequent hyperglycemia. Additionally, a reduction in lean mass could also confer
hyperglycemia as skeletal muscle is primarily responsible for glucose excursion. In the
present study, I found that PCB exposure during the critical periods of periconception,
gestation, and lactation engenders sex-specific and age-dependent perturbations of
glucose homeostasis.
3.3 Materials and Methods
3.3.1 Animals and Diets

The experiments were performed in accordance with an

approved Institutional Animal Care and Use Committee protocol at the University of
Kentucky.

Experimental dams and offspring are the same as those in a published

manuscript [291]. In summary, female ICR mice which had previously delivered one
litter were purchased from Taconic at approximately 4 months of age. Dams were
maintained on a low fat 10% Kcal diet (D12450B, Research Diets, New Brunswick, NJ)
ad libitum for duration of study. One ICR sire was mated to two dams for one week.
Pups were culled to 6 on postnatal day 3 and cross-fostering was employed whose litters
had less than 6 pups to equilibrate nutrient availability. Mice were weaned onto standard
chow (#2018, Teklad Global 18% Protein Rodent Diet) at 3 weeks of age and males were
housed 3 per cage, and females were housed 5 per cage.
3.3.2 PCB exposure PCB 126 (3, 3’, 4, 4’, 5-pentachlorobiphenyl) was purchased from
AccuStandard (C-126N, New Haven, CT). Dams were treated with either tocopherolstripped safflower oil (vehicle) or 1 μmole/kg PCB 126 biweekly beginning 48 hours
prior to mating [291].
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3.3.3 Glucose tolerance test For all experimental procedures performed on offspring,
only one male and one female per litter were used. At 7 weeks, 6 months, and 9 months
of age glucose tolerance tests were performed on the offspring. Mice were fasted prior to
glucose tolerance tests beginning at lights on. During glucose tolerance tests, mice were
either orally gavaged (OGTT) or injected intraperitoneally (IPGTT) with 2 g/kg Dextrose
(Bimeda, Le Sueur MN). Blood glucose was measured by tail vein venipuncture using an
Ascensia Breeze 2 meter (Bayer, Mishawaka, IN) just prior to dextrose administration for
baseline measurement. Blood was sampled again 15, 30, 60 and 120 minutes after
glucose administration. For glucagon like peptide-1 (GLP-1) receptor antagonist studies,
Exendin Fragment 9-39 (Ex-9) was purchased from Sigma (E7269) and administered at a
dose of 5 μg in 200 μl sterile PBS 30 minutes prior to oral glucose tolerance test.
3.3.4 Insulin tolerance test Recombinant human insulin (Novolin) was used for insulin
tolerance tests. Males and females were given 1.25 and 0.75 IU/kg insulin diluted in
sterile phosphate buffered saline (PBS) intraperitoneally (IP), respectively. Mice were
fasted at lights on for 3 hours prior to insulin administration.

Blood glucose was

measured via glucometer just prior to insulin administration and again 15, 30, 60, 120
and 180 minutes after insulin injection.
3.3.5 Pyruvate tolerance test Pyruvate tolerance tests were performed to indicate rate of
gluconeogenesis. Pyruvate dissolved in sterile saline was injected IP at a concentration
of 2 g/kg after 3 hours of fasting into female offspring. Blood glucose was measured in
tail vein every 30 minutes for 3 hours. Again, the baseline measurement was taken just
prior to pyruvate administration.
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3.3.6 Statistics

IBM SPSS statistics 20 software was used for repeated measures

ANOVA for determining significance in experiments in which repeated samples were
taken from a single mouse, as in the case of glucose, insulin and pyruvate tolerance tests.
In the case that repeated measures identified a significant difference between groups, then
OneWay ANOVA was performed for comparing the treatment groups at each time point.
Areas under the curve were determined by SigmaPlot 12.0 software. Grubbs’ Test was
performed using GraphPad software to identify significant outliers which were excluded
from further statistical analyses. Those animals whose area under the curve (AUC) was a
significant outlier were removed for subsequent statistical analyses. Students T-test was
used to determine significance between the areas under the curve of treatment groups.
3.4 Results
3.4.1 PCB-induced disruption of glucose homeostasis in gender specific and timedependent At 7 weeks of age a glucose tolerance test was performed on both male and
female offspring following a 3 hour fast. Male offspring displayed differences in glucose
homeostasis (Figure 3.1A). Upon an oral glucose challenge, maternal PCB exposure
resulted in impaired glucose tolerance in male offspring compared to controls. The AUC
between the males born to dams exposed to 1 μmole/kg PCB 126 was increased 31%
compared to controls, p=0.041 (Figure 3.1B) signifying attenuation of glucose disposal
more than 4 weeks after the last perinatal PCB exposure. The PCB-exposed female
offspring showed a trend toward impaired glucose disposal upon the experimental oral
glucose challenge (Figure 3.1C) (p=0.069 and 0.162 for repeated measures ANOVA and
AUC T-test, respectively). The female offspring born to PCB-exposed dams also had
significantly elevated fasting blood glucose values.
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At six months of age, both male and female offspring were fasted for 3 hours
prior to administering oral glucose tolerance tests. Male offspring revealed no difference
in glucose tolerance upon an oral glucose challenge (Figure 3.2A and 3.2B). The females
born to dams perinatally exposed to 1 μmole/kg PCB 126 displayed impaired glucose
tolerance, p=0.038 and p=0.055 for repeated measures ANOVA and AUC T-test,
respectively (Figure 3.1D). Perhaps with a larger sample size, the AUC would have
demonstrated statistically significant impairment in glucose homeostasis as well.
The male offspring control animals after 6 months of age displayed an
overabundance of variability rendering it impossible to discern any statistically
significant difference between them and PCB-exposed offspring regarding glucose
tolerance. For this reason, male glucose tolerance data were not analyzed after 6 months
of age and subsequent glucose tolerance tests were performed only on females born to
vehicle and 1 μmole/kg PCB 126 exposed dams (Figures 3.4 and 3.5).
3.4.2 Insulin tolerance is comparable between treatment groups

Insulin tolerance tests

were employed to investigate whether impairments in glucose disposal were the result of
insulin resistance. Blood glucose was monitored in both male and female offspring at 8
months of age following IP injection with insulin. Both sexes experienced declines in
blood glucose at similar rates between vehicle and PCB exposed groups (Figure 3.3).
Male offspring born to vehicle treated dams appeared to have higher levels of blood
glucose beginning at baseline and continuing throughout the tolerance test, but the
amount of variability in the controls made any difference statistically insignificant. The
results from the insulin tolerance tests eliminate insulin resistance as an underlying
mechanism of perinatal PCB-induced hyperglycemia.
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3.4.3 Fasting time and route of glucose administration affect glucose tolerance in female
offspring In aged females, glucose intolerance persisted in PCB exposed mice and was
shown to reach statistical significance at 9 months of age (Figure 3.4). Interestingly,
disruption of glucose homeostasis was only observed when the glucose was administered
orally after a 3 hour fast (Figure 3.4A and 3.4B) because when glucose was injected IP,
there were comparable glucose disposal rates between vehicle and PCB exposed
offspring (Figure 3.4C). Additionally, when aged female offspring were administered
glucose orally following an overnight 16 hour fast, there were again comparable rates of
glucose disposal (Figure 3.4D). Taken together, these data illustrate disruption of an
early event in glucose ingestion, one that occurs most likely prior to glucose appearance
in the blood stream. This is further evidenced by the observation that the earliest time
point after glucose challenge is the most severely impaired.
3.4.4 GLP-1 receptor antagonism does not extinguish PCB-induced glucose intolerance
in female offspring Exendin Fragment 9-39 (Ex 9) is a competitive antagonist of the
GLP-1 receptor. GLP-1 is secreted by L cells of the gut after a meal and signals in an
endocrine fashion to slow gastric emptying and augment glucose-stimulated insulin
secretion. The impairment in glucose tolerance is at the earliest time point, suggesting the
bolus of glucose was absorbed into the bloodstream more quickly and completely in the
female offspring born the PCB exposed dams than in the controls. Because GLP-1 slows
gastric emptying, if impaired GLP-1 signaling was contributing to glucose intolerance,
antagonism of the GLP-1 receptor would diminish glucose intolerance and result in
comparable glucose tolerance curves, particularly at the 15 minute time point. The GLP56

1 receptor was inhibited by Ex-9 30 minutes prior to commencement of an oral glucose
tolerance test. All mice were given Ex-9 due to the small sample size and inherent
variability of the experiment. The effect of the Ex-9 was seen by the nearly identical
43% and 45% increase in blood glucose in the 30 minutes between Ex-9 injection and
glucose administration. GLP-1 receptor antagonism mitigated much of the disturbance in
glucose tolerance following an oral glucose challenge, p=0.225 and 0.468 for repeated
measures and AUC, respectively.

Antagonism of the GLP-1 receptor appeared to

extenuate glucose intolerance yet the large impairment at 15 minutes post gavage
remained, p=0.016 at that time point (Figure 3.5A).
3.4.5 Rate of gluconeogenesis is not different after 3 hour fast

Hepatic glucose

production (HGP) consists of glycogenolysis and gluconeogenesis, the latter utilizing
pyruvate for de novo synthesis of glucose to be taken up by the periphery. The pyruvate
tolerance test functions as an indirect measure of gluconeogenesis. Because glucose
intolerance was observed after 3 hours of fasting and not 16 hours, this approach was
used to investigate early initiation of HGP as a contributor to the glucose intolerant
phenotype of perinatally PCB exposed female offspring.

Figure 3.5B illustrates

comparable blood glucose levels after pyruvate administration following a 3 hour fast,
p=0.465 and 0.449, for repeated measures and AUC, respectively.
3.5 Discussion
The impairment in glucose tolerance observed at 7 weeks of age in perinatally
exposed male offspring is likely due to direct exposure of PCBs through the breast milk.
The partitioning of PCB 126 in goat kids upon maternal PCB exposure during gestation
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and lactation revealed undetectable serum levels at birth but modest amounts at weaning
[188]. Additionally, at 40 weeks of age, goat kids showed sequestration of PCB 126 in
the liver as compared to adipose tissue and they determined its half-life to be 4 months
[188]. Baker et al showed direct exposure of dioxin-like PCBs 77 and 126 elicit glucose
intolerance and insulin resistance in male C57BL/6 mice [186].

Because insulin

tolerance tests were not performed on the male offspring at the time of glucose
intolerance, we cannot ascertain the role of insulin in PCB-induced hyperglycemia.
Female offspring born to PCB-exposed dams exhibited glucose intolerance at
older ages, suggesting PCB-induced fetal programming of glucose intolerance rather than
direct effects of PCB on glucose homeostasis. Impairment in glucose tolerance in female
offspring upon an oral glucose challenge but not an IP glucose challenge, as well as its
sensitivity to changes in fasting time, point to splanchnic system dysfunction rather than
insulin resistance [192]. The insulin tolerance test results are evidence that perinatal PCB
exposure does not impair insulin sensitivity. This is corroborated by Lee et al. who
showed in a 2007 analysis of 1999-2002 NHANES data, that dioxin-like PCBs are not
associated with HOMA-IR, an index of insulin resistance, in non-diabetic Americans
[121]. Additionally, a case control study found no association between reference PCB
153 and insulin-dependent diabetes [292]. In further support of this is the fact that
glucose reaches the pancreas in both routes of glucose administration, such that if there
were impairment in glucose-stimulated insulin secretion, the disruption should be
observed in both oral and IP glucose tolerance tests.
The pyruvate tolerance test reveals that gluconeogenesis is not affecting glucose
tolerance, deducing hepatic glucose uptake as possible underlying mechanism of the
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observed hyperglycemia.

Studies have shown an involvement of the AhR in the

development of the hepatic vasculature, specifically “failure of ductus venosus closure”
resulting in hypoperfusion of the liver [293, 294]. If this effect of the AhR on liver
development follows a U-shape, characteristic of endocrine disruptors, then it is possible
that over activation of the receptor, too, could result in hepatic hypoperfusion and
attenuated HGU. This phenomenon is also observed in hypoxic intrauterine growth
restricted fetuses in order to spare nutrients for the proper development of more important
organs like the brain [194, 226].
In conclusion, humans are exposed to persistent organic pollutants such as PCBs
in our first environment, the womb of our mothers. Although this exposure continues for
most likely the duration of our lives, the ramifications of early life pollutant exposure
may not manifest until later in life. The present study demonstrated perturbations of PCB
exposure on later life glucose homeostasis in both male and female offspring born and
nursed to PCB exposed dams. More studies are needed to assess the contribution of preweaning xenobiotic exposure on the etiology of diabetes.
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Figure 3.1. OGTT in offspring at 7 weeks of age. Mice were orally gavaged with 2 g/kg
glucose after 3 hour fast. A) OGTT in male offspring; n=11 and n=12 for Control and
PCB groups, respectively. Repeated measures p=0.038 B) Area under curve for OGTT
of male offspring, p<0.05. C) OGTT in female offspring; n=11 and n=10 for Control and
PCB groups, respectively. Repeated measures p=0.069. D) Area under curve for OGTT
of female offspring. * indicates p<0.05 and ** indicates p<0.01.
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Figure 3.2. OGTT in offspring at 6 months of age. Mice were orally gavaged with 2 g/kg
glucose after 3 hour fast. A) OGTT in male offspring; n=10 and n=11 for Control and
PCB groups, respectively. Repeated measures p=0.494 B) Area under curve for OGTT
of male offspring. C) OGTT in female offspring; n=11 and n=11 for Control and PCB
groups, respectively. Repeated measures p=0.038. D) Area under curve for OGTT of
female offspring, p=0.055. * indicates p<0.05.
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Figure 3.3. ITT in offspring at 8 months of age. Mice were fasted for 3 hours prior to
insulin administration. A) Male offspring were IP injected with 1.25 IU/kg insulin; n=9
and n=10 for Control and PCB groups, respectively. B) Female offspring were IP
injected with 0.75 IU/kg insulin; n=11 and n=10 for Control and PCB groups,
respectively.
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Figure 3.4. GTT in female offspring at 9 months of age. A) OGTT in female offspring;
n=11 and n=9 for Control and PCB groups, respectively. Repeated measures p=0.019 B)
Area under curve for OGTT of female offspring, p<0.05. C) IPGTT in female offspring;
n=12 and n=9 for Control and PCB groups, respectively. D) OGTT of female offspring
following an overnight (16 hour) fast; n=12 and n=9 for Control and PCB groups,
respectively. * indicates p<0.05.
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Figure 3.5. Splanchnic investigation. A) Female mice 1 year of age were administered
GLP-1 receptor antagonist Ex-9 30 minutes prior to OGTT; n=12 and n=9 for Control
and PCB groups, respectively. Repeated measures p=0.225. B) Pyruvate tolerance test
was conducted on female offspring 1 year of age. Mice were injected IP with 2 g/kg
sodium pyruvate and blood glucose measured every half hour for 3 hours; n=12 and n=9
for Control and PCB groups, respectively. * indicates p<0.05
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CHAPTER 4
MATERNAL PCB EXPOSURE AFFECTS HEPATIC GENE EXPRESSION OF
MOUSE DAM AND OFFSPRING BOTH IN UTERO AND AT 4 MONTHS OF
AGE
4.1 Abstract
Polychlorinated

biphenyls

(PCBs)

are

environmental

pollutants

whose

bioaccumulation and transplacental transfer results in exposure during critical windows
of development which may cause reduced birth weight.

The liver functions in

macronutrient energy homeostasis and xenobiotic detoxification, and previous studies
found changes in body composition and glucose tolerance upon perinatal PCB exposure.
I therefore investigated effects of gestational PCB exposure on intrauterine growth and
alterations in hepatic gene expression. Female ICR/CD1 mice were gavaged biweekly
with 1 μmole/kg PCB 126 or safflower oil vehicle.

In one cohort, females were

euthanized at embryonic day 18 and pup and placental weights recorded. Also, livers
were harvested from both non-pregnant and pregnant dams and cesarean pups. In a
second cohort, dams were allowed to deliver and nurse their litters, and offspring livers
were collected at 4 months of age (from breeding study in Aims 1-2). There were no
differences in fetal body or placental weights. Absolute mRNA quantification revealed
upregulation of dipeptidyl peptidase 4 along with canonically aryl hydrocarbon receptor
(AhR) regulated genes cytochrome P450 (Cyp) 1a1, Cyp1b1, NAD(P)H quinone
oxidoreductase 1 (NQO1) and nuclear factor erythroid-derived 2-like 2 (Nrf2) in livers of
non-pregnant females, dams, and cesarean pups. PCB gavaged mice also displayed
attenuated insulin-like growth factor binding protein 2 (IGFBP2) and alterations in genes
involved in oxidative stress and macronutrient metabolism. Four month old offspring
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exhibited decreased insulin-like growth factor (IGF) 1 expression and increased
expression of Cyp1a1 and stress related genes, autophagy related protein 7 (Atg7) and
DNA damage-inducible transcript 3 (CHOP) without any detectable PCB in their livers.
Key findings in the study are significant changes in hepatic gene expression in adult
offspring perinatally exposed to PCB even in the absence of any detectable parent
compound or metabolite; and PCB-induced regulation of genes linked to metabolic
disease states, DPP4 and IGFBP2.
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4.2 Introduction
Polychlorinated biphenyls (PCBs) are a class of environmental pollutants whose
lipophilicity and resistance to biodegradation enables biomagnifications in the food chain
and resulting in lifetime of dietary exposure [181, 190]. PCB exposure begins in utero
rather than after birth. These toxicants have been found in the placenta, cord blood and
breast milk, signifying a continuum of exposure during perinatal development [278, 295299]. Many animal studies employing PCBs often begin exposure after birth, which is not
entirely exemplary of the human experience in that it dismisses a critical period when
relatively small exposures are aggrandized and have potentially incessant repercussions.
In fact, several studies in humans have correlated prenatal PCB exposure with low birth
weight in offspring indicating PCB-induced developmental perturbations [182, 199, 200,
248-251].
Moreover, dioxin and dioxin like PCBs activate the AhR and studies have
demonstrated a role of this xenobiotic receptor in hepatic organogenesis with AhR
deficient animals exhibiting aberrant hepatic histology and attenuated perfusion [300304]. Because the liver is the site of xenobiotic detoxification and central to energy
homeostasis, I sought to investigate alterations of hepatic gene expression in murine
offspring perinatally exposed to 3,3’,4,4’,5 pentachlorobiphenyl (PCB 126).
The classical and most studied ligand of the AhR is 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD) or more commonly referred to as simply dioxin. Several studies have
examined dioxin-induced alterations of hepatic gene expression [305-316]. Both in vitro
and in vivo experiments confirm dioxin mediated induction of classical AhR responsive

67

genes cytochrome P450, 1a1 (Cyp1a1), 1b1 (Cyp1b1), and NAD(P)H dehydrogenase
quinine 1 (NQO1) but genes involved in energy homeostasis and oxidant metabolism
may be species and cell source specific [309, 311, 313-316]. AhR binding and nuclear
translocation necessitates dioxin-induced hepatotoxicity and consequently studies have
focused on dioxin-induced gene expression mediated by ligand binding [317-319].
However, Tijet et al in their investigation of TCDD-induced gene batteries demonstrated
that some genes are regulated by AhR independent of TCDD, while others are regulated
by TCDD when AhR is lacking, illustrating transcriptional modulation in the absence of
canonical ligand:receptor activation [310].
Ovando et al. compared hepatic toxicogenomic effects of TCDD, PCB 126, and
non-dioxin-like PCB 153 using a chronic exposure model in female Sprague Dawley rats.
The rats were exposed to 100 ng/kg/day TCDD, 1000 ng/kg/day PCB 126, or 1000
μg/kg/day PCB 153 5 days per week for 13 or 52 weeks and of the 75, 70, and 9 genes,
respectively, that were significantly regulated upon toxicant exposure at both time points,
only 42 were shared between TCDD and dioxin-like PCB 126 [320].

These data

accentuate the flaw in extrapolating dioxin-induced gene expression to dioxin-like PCBmediated gene expression. Additionally, these studies fail to elucidate alterations in
hepatic gene expression during fetal and postnatal development which contains critical
periods of anatomical and epigenetic progression. As a result, PCB exposure during
these windows of plasticity will likely exhibit changes in gene expression secondary and
perhaps tertiary to AhR activation resulting from perturbed development.

Previous

studies employing this low dosing PCB exposure model have revealed sex-specific
alterations in offspring body composition, and unpublished glucose and insulin tolerance
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data alludes hepatic dysfunction. In the current experiment, I showed biweekly PCB 126
exposure at 1 μmole/kg alters hepatic gene expression in dam, fetal and offspring livers.
4.3 Methods:
4.3.1 PCB exposure during pregnancy These experiments were performed with the
approval of the Institutional Animal Care and Use Committee at the University of
Kentucky. Female CD1 mice were acquired from Taconic at approximately 4 months of
age after having previously delivered one litter. Mice were fed a semi-purified low fat
diet, 10% Kcal from fat (Research Diets D12450B) ad libitum beginning 2 weeks prior to
mating. Male CD-1 breeders were also purchased from Taconic, and were fed low fat
diet prior to mating. 48 hours prior to mating, female dams were exposed to male
bedding in order to induce estrous. Female mice were then placed in the cage of a male
breeder. Mating was permitted to commence overnight, at which time male mice were
removed.

On embryonic day zero dams were gavaged with 1 μmole/kg PCB 126

(AccuStandard, C-126N New Haven, CT) dissolved in tocopherol-stripped safflower oil
(Dyets # 403952 Bethlehem, PA). A second dose was administered 14 days after the first
oral exposure. This exposure was then on embryonic day 14. On embryonic day 18.5,
mice were sacrificed, and there was no dam that delivered her litter prior to takedown.
Livers were taken from both pregnant and non-pregnant dams. Also, the number of
fetuses per dam was counted. Fetuses were weighed as well as their respective placentas.
Livers were excised from the 2 most distal fetuses on each uterine horn as the position of
the fetus within the uterus affects nutrient availability and perhaps subsequent hepatic
gene expression. Tissues were snap frozen in liquid nitrogen until further processing.
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4.3.2 PCB exposure of 4 month old offspring In a separate cohort of mice (same breeding
paradigm as Aim 1 and 2), female ICR mice which had previously delivered one litter
were purchased from Taconic at approximately 4 months of age. Dams were maintained
on a low fat 10% Kcal diet (D12450B, Research Diets, New Brunswick, NJ) ad libitum
for duration of study. One ICR sire was mated to two dams for one week. Dams were
exposed bi-weekly to tocopherol-stripped safflower oil (vehicle) or 1 μmole/kg PCB 126
from 48 hours prior to mating until weaning. Pups were culled to 6 on postnatal day 3
and cross-fostering was employed whose litters had less than 6 pups to equilibrate
nutrient availability. Mice were weaned onto standard chow (#2018, Teklad Global 18%
Protein Rodent Diet) at 3 weeks of age and males were housed 3 per cage and females
were housed 5 per cage. In this separate cohort, mice were mated for 1 week rather than
overnight, therefore the day of gestation which dams were gavaged cannot be determined.
At 4 months of age, a group of these mice were sacrificed; livers were collected and snap
frozen until further processing.
4.3.3 PCB quantification Approximately 45 mg of liver was homogenized in 200 μl
deionized water using 3 stainless steel 5/32” grinding balls and Geno/Grinder (SPEX
Sample Prep) at 1250 rpm for 45 seconds. Eight hundred microliters of cold acetonitrile
and 50 μl of 10μM

13

C labeled PCB 126 were added to homogenate with the latter

serving as an internal standard. This solution was vortexed for 5 minutes, sonicated for
30 seconds in water bathe sonicator, then centrifuged for 5 minutes at 15,000 rpm.
Superntant was transferred to a glass vial. This disruption was repeated on the pellet
twice with 1 ml cold acetonitrile and 1 ml 50% cold acetonitrile, respectively.
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Supernatants were pooled, dried under nitrogen and reconstituted in 100 μl of 99/1
methanol/water + 0.5% formic acid + 0.1% ammonium formate solution.
Liquid chromatography-tandem mass spectrometry of the reconstituted samples
from vehicle and PCB exposed animals was performed by Manjula Sankara under the
supervision of Dr. Andrew Morris. The following is their protocol for this procedure.
PCB 126 and hydroxy PCB 126 were measured using a Shimadzu
UFLC coupled with an AB Sciex 4000-Qtrap hybrid linear ion trap triple
quadrupole mass spectrometer in multiple reaction monitoring (MRM)
mode. 13C12 PCB 126 was used as internal standard for PCB 126 and
hydroxy PCB 126 measurements. The mass spectrometer was operated in
the positive APCI mode for PCB 126 measurements and in negative ESI
mode for hydroxy PCB 126 measurements with optimal ion source settings
determined by synthetic standards. PCB 126 was analyzed using Kinetex
2.6 u C18, 100 A, 100 X 2.10 mm (Phenomenex) column. The mobile
phase consisted of water as solvent A and acetonitrile as solvent B. For
the analysis of PCBs the separation was achieved using a gradient of 20
% B to 60 % B for 1 min, 60% B to 100% B in the next 7 min, and
maintained at 100% B for the last 2 min with a flow rate of 0.25 ml/min.
MRM transitions monitored were as follows: 325.9/256.1; 325.9/254.1
and 325.9/184 for PCB 126; and 338/268.1; 338/196.1 and 338/265.7 for
13C12 PCB 126. In the MRM ion transition the precursor ion represents
the MЀ· and the product ion represents either [M-Cl] Ѐ or [M-2Cl] Ѐ.
Hydroxy PCB 126 was analyzed using Luna 3 u C18 (2), 100 A, 250 X
2.00 mm (Phenomenex) column with a flow rate of 0.25 mL/min. The
mobile phase consisted of 75/25 of methanol/ water with formic acid
(0.5%) and 5 mM ammonium formate (0.1%) as solvent A and 99/1of
methanol/ water with formic acid (0.5%) and 5 mM ammonium formate
(0.1%) as solvent B. Hydroxy PCB 126 was eluted using a gradient of 10
% B to 100 % B in 4 min and maintained at 100% B for the next 11 min.
MRM transitions monitored were as follows: 340.8/340.9 for hydroxy
PCB 126 and 386.8/340.9 for dihydroxy PCB 126. Precursor ion of the
ion transition is a formic acid adduct: [M+FA-H]- and product ion is [MH]-.
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4.3.4 RNA isolation Total RNA was extracted from liver samples using either Qiagen
RNeasy mini kits or Qiagen RNeasy lipid tissue mini kit. Approximately 30mg of tissue,
three stainless steel 5/32” grinding balls and appropriate volume lysis buffer as indicated
in the instructions was added to 2 ml tubes. Samples were disrupted and homogenized
using Geno/Grinder (SPEX Sample Prep) at 1250 rpm for 30 seconds. Total RNA was
silica-membrane purified from lysed homogenate according to manufacturer’s protocol.
Tissue RNA quality was determined using Bioanalyzer and only RNA with an RNA
Integrity Number above 7 was used for Nanostring gene expression analysis.
4.3.5 Nanostring gene expression

Nanostring technology uses capture and reporter

probes specific to an mRNA sequence in a codeset to quantify the number of message
RNA in a given sample. This technology can quantify over 500 genes in a given sample
simultaneously in a given codeset. We picked over a hundred genes to investigate
changes in hepatic gene expression across the stages of development.

We used 2

different codesets and 2 different quantities of RNA. For a complete list of genes in each
codeset, reference Tables 4.8 and 4.9. One hundred nanograms of RNA were run on the
first codeset in which RNA from pregnant dam and fetal livers were used. On the second
codeset, 750 nanograms of RNA from non-pregnant dam livers and 4 month old offspring
livers were used. All of the target genes in the first codeset that showed significant
changes in gene expression were included in the second codeset, along with several
others.
4.3.6 Quantification of gene expression Manipulation of the raw counts from Nanostring
was required to take into account variability in the amount of RNA used, and also the
relative expression to housekeeping genes. To do this, the sums of the positive controls
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for each sample were averaged. The sums of the samples’ positive controls were then
divided by this mean to obtain the first scaling-factor. A samples’ count for a particular
gene was then subtracted by its maximum negative control value and this difference was
then multiplied by the first scaling factor. Housekeeping genes whose p value between
treatment groups was greater than 0.5 and whose coefficient of variation across treatment
groups was determined to be less than 0.5 were selected as reference genes. For each
sample, the geometric mean of the reference genes were calculated and averaged across
samples. This mean was then divided by the sample’s respective geometric mean to
obtain the second scaling factor. The adjusted counts were then multiplied by this second
scaling factor, and it is these final values that were used in statistical analyses of gene
expression.
4.3.7 Quantitative Real-time PCR Quantitative Real-Time PCR (qPCR) was performed
to validate NanoString nCounter results. Four hundred nanograms of RNA were reverse
transcribed using qScript cDNA SuperMix (Quanta Biosciences 95048). Primers were
purchased from Eurofins MWG Operon (Table 4.8). Real-Time PCR was performed
using PerfeCta SYBR Green FastMix Low Rox (Quanta Biosciences 101414) master mix
and Stratagene Mx3000P real-time instrument. The 2¨¨CT method was used to calculate
the relative quantity (RQ) with the mean of control samples as the calibrator.
4.3.8 Statistics Fetal and placental weights were averaged such that each dam had an
average fetal weight and an average placental weight, and these means were used in
statistical analyses of pregnant dam parameters (Table 4.1). Students T-test was used to
make comparisons between PCB treated and control animals.
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Interactions between

gender and PCB treatment were determined using 2way-ANOVA in SigmaPlot 12.0
software.
4.4 Results
4.4.1 PCB treatment does not affect fetal or placental weights Biweekly PCB 126
exposure did significantly affect dam, fetus, or placenta weights (Table 4.1). There was
however a trend toward increased placenta weights upon PCB exposure (p=0.07).
Placental weights often correspond with birth weight, such that heavy babies have
heavier placentas and small babies have lighter placentas. This same trend is evident in
this exposure model; PCB exposed fetuses weigh more than control fetuses, although this
is difference is not statistically significant (p=0.226). The decreased number of fetuses
per dam may account for this slight increase in mean fetus and placenta weight, as parity
affects fetal weight. My hypothesis that PCB exposure would cause lower birth weight
did not come to fruition in this mouse model and PCB dosing paradigm, if one is to
extrapolate the data from late gestation.
4.4.2 Quantification of PCB 126 and hydroxyl metabolite Figure 4.1 displays amount of
parent compound detected in the livers of the samples tested. Female mice gavaged with
PCB that did not become impregnated had the highest average liver burden of parent
compound at 20.96 pmol/mg wet weight, followed by pregnant dams at 6.16 pmol/mg
with 1 of 9, and 6 of 9 samples having PCB levels below the limit of detection,
respectively. Only 1 of 9 fetal livers had detectable PCB 126 and its concentration was
53.52 pmole/mg. PCB levels in control animals were all below the limit of detection.
Moreover, there was no hydroxy-PCB metabolite detected in any of the samples.
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4.4.3 Differential gene expression in dams administered PCB 126 PCB exposure during
pregnancy resulted in 25 of 120 genes being differentially expressed. The first codeset
primarily included genes involved in detoxification, stress response, epigenetics and lipid
and carbohydrate metabolism. Table 4.2 shows the genes that were changed upon PCB
126 exposure during pregnancy. The genes are arranged in ascending order regarding the
PCB/control ratio, beginning with the genes most downregulated and ending with the
genes most upregulated. This is the arrangement for all of the gene expression tables.
Maternal PCB 126 increases expression of detoxifying enzymes Cyp1a1 and Cyp1b1 as
is expected upon AhR activation. Furthermore, Nuclear factor erythroid-derived 2-like 2
(Nrf2) and NAD(P)H quinone reductase 1 (NQO1) are increased, signifying interplay
between the Nrf2 and AhR transcription factors [225, 321]. In addition to xenobiotic
detoxifying cytochrome P450s being increased upon PCB exposure, antioxidative gene
expression was increased (glutathione-s-transferase a1 (Gsta1), glutathione-s-transferase
mu 4 (Gstm4), glutathione peroxidase (Gpx1), and catalase (Cat)). The majority of genes
whose expression was decreased were involved in lipid metabolism e.g. perilipin 2
(Plin2), carnitine palmitoyltransferase 1a (CPT-1A), acetyl-CoA carboxylase 1 (ACC1),
and peroxisome proliferator-activated receptor alpha (3SDUĮ However, other genes such
as insulin-like growth factor (IGFBP2) and lactase dehydrogenase A (LDHA) were also
decreased.
4.4.4 Non-pregnant mice display modulation of macronutrient metabolism PCB exposed
female mice that did not get pregnant revealed interesting gene expression patterns as
well. Of the 129 gene included on the 2nd codeset, 26 were changed upon PCB exposure.
Again, cytochrome P450 enzymes involved in xenobiotic detoxification, Cyp1a1 and
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Cyp1b1, as well as Nrf2 and NQO1 were significantly increased compared to controls.
Genes involved in lipid homeostasis were attenuated, including fatty acid synthase (Fasn)
and ACC1 and glucose-6-phosphate dehydogenase (G6PD). There appears to be an
increase in glucose uptake in the PCB exposed tissues as glucose transporter 1 (GLUT1)
is significantly increased.

GLUT2 is increased by 13% compared to controls also,

although this increase is not statistically significant, p=0.060. Increases in glycolytic
genes hexokinase 3 (HK3) and phosphoglycerate kinase 1 (Pgk1) indicate possible
increased glycolysis, but the decreased expression of glycogen synthase 2 (Gys2) and
glycogen phosphorylase (Pygl) suggest neither glycogen synthesis nor glycogenolysis is
increased, respectively. Glycogen synthesis however is not particularly transcriptionally
regulated, as phosphorylation events related to insulin and glucagon signalling are
responsible for regulation of glycogenesis [6, 23]. The decreased expression of G6PD
also suggests less divergence of phosphorylated glucose to the pentose phosphate
pathway. Figure 4.2 is a Venn diagram of the genes that are differentially expressed in
pregnant and non-pregnant mice. The genes expressed in both pregnant and non-pregnant
animals administered PCB are those involved in detoxification, either xenobiotic or
oxidative.
4.4.5 Fetal livers respond to PCB exposure in utero Any changes in fetal liver gene
expression upon maternal PCB administration is either through direct transplacental
exposure to the toxicants or a response to a disrupted intrauterine environment as a
consequence of a maternal response to the dioxin-like PCB. Table 4.4 displays genes that
are significantly changed between those conceived by dams exposed to vehicle versus
those exposed to 1 μmole/kg PCB 126. Xenobiotic and oxidative detoxification genes
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were increased in fetal livers maternally exposed to PCB including cytochrome P450s,
Gstm4, NQO1, peroxiredoxin-1 (Prdx1), and Cu-Zn superoxide dismutase (SOD1), but
genes involved in glucose homeostasis exhibited attenuated expression (GLUT1 and
lactate dehydrogenase type A (LDHA)).

Figure 4.1 compares and contrasts gene

expression among livers from non-pregnant and pregnant PCB exposed dams and the
livers of fetuses. Interestingly, excluding the 4 marker genes (Cyp1a1, Cyp1b1, Nrf2 and
NQO1) only dipeptidyl-peptidase 4 (Dpp4) gene expression was increased. Dpp4 plays a
major role in glucose homeostasis by rapidly degrading the gut hormone, or incretin,
glucagon-like peptide 1 (GLP-1) [32, 40, 322]. GLP-1 is secreted upon feeding and
slows gastric emptying and potentiates glucose-stimulated insulin secretion [322, 323].
Increased Dpp4 expression and translation could augment glucose excursion and
contribute to hyperglycemia. Together, the upregulation of Cyp1a1, Cyp1b1 and NQO1
point to direct activation of the fetal AhR and transactivation of these genes afforded by
transplacental transport of PCB 126.
4.4.6 Maternal PCB exposure alters hepatic gene expression in 4 month old offspring
Recall that these offspring were born to dams that were exposed to PCB 126 forty-eight
hours prior to mating and biweekly thereafter until weaning. These offspring were thus
exposed during lactation in addition to transplacental exposure in utero. Alterations in
hepatic gene expression persist in these animals. Across gender, perinatal PCB exposure
decreased expression of hypoxia-inducible factor 1a (Hif1a) and insulin-like growth
factor 1 (IGF1) and increased expression of autophagy related protein 7 (Atg7), C/EBP
homologous protein (CHOP), insulin-like growth factor 1 receptor (IGF1R), and Cyp1a1
(Table 4.5). The divergent expression of IGF1 and its receptor was likely compensatory.
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CHOP and Atg7 are involved in endoplasmic reticulum stress and autophagy,
respectively [324, 325]. Cyp1a1 expression suggests direct exposure to PCB 126 or
constitutive activation of the AhR, perhaps mediated by epigenetic mechanisms. Both
male and female offspring exhibit a general decrease in gene expression, Tables 4.6 and
4.7, respectively. Only four genes are different in male offspring born to vehicle or PCB
exposed dams, and interestingly one is DNA methyltransferase 1 (Dnmt1). If there were
decreased DNA methylation in these livers, one might expect increased gene expression,
but this is not the case. Female offspring have 8 genes differentially expressed and only
2 are upregulated, Nrf2 and Peroxisome proliferator-activated receptor gamma (Pparg).
Igf1 and the insulin receptor (Insr) are both decreased demonstrating a possible
hypoproliferative or hypotrophic state in these livers.

Two-way ANOVA revealed

significant interactions between gender and 5 genes, Insr, beta-2-microgobulin (B2m),
CPT1A, Prdx1, and the mineral corticoid receptor (MCR). Only MCR was differentially
expressed in males while the others were specific to females.
4.4.7 NanoString nCounter results were validated with Real-Time PCR Quantitative
real-time PCR was performed to validate gene expression. Cyp1a1 and NQO1 were
selected as verifier genes because it was not feasible to perform RT-PCR for every gene
that was changed and these 2 genes are expressed during canonical AhR activation.
Real-time PCR shows changes in gene expression comparable to those observed using
absolute mRNA quantification via NanoString nCounter (Table 4.9).
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4.5 Discussion
The object of the present study was to elucidate changes in hepatic gene
expression upon perinatal PCB exposure as may be secondary to PCB-induced
intrauterine growth restriction and subsequent abnormal liver physiology. The effects of
PCB 126 on gene expression in livers was compared in female CD-1 mice, pregnant CD1 dams, gestational day 18.5 fetuses, and 4 month old male and female offspring. Over
one hundred genes were selected on 2 Nanostring codesets representing various
biological processes, including but not limited to, xenobiotic and oxidant detoxification,
inflammation, epigenetics, and metabolism of carbohydrates and lipids. Also, to evaluate
the contribution of ligand activated AhR-dependent gene transcription, PCB 126 was
measured in these tissues.
Intrauterine growth restricted animals are often small in respect to their
gestational age and also small infants are usually accompanied by small placentas [326].
Because studies have shown that PCB exposure is inversely associated with birth weight,
we hypothesized that gestational PCB exposure would result in fetuses and placentas that
were smaller at gestation day 18.5. In the present study, however, I did not observe
statistically significant differences in fetal weight or placenta weight. In fact, there were
trends toward increased fetal and placental weights which are likely due a decrease in the
number of fetuses per dam in the PCB exposed animals, although this too is not
statistically significant. One of the drawbacks to this animal model is that PCB levels in
the dams are distributed across many fetuses, while in singleton offspring this not the
case. As a result, the toxicant transfer to the developing murine fetus is likely less than
expected in singleton pregnancies.
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Direct exposure to 1 μmole/kg PCB 126 via oral gavage resulted in changes in
gene expression similar to those in previous studies using TCDD for AhR activation.
Ligand-activated AhR has consistently been shown to activate gene transcription of
detoxifying enzymes Cyp1a1, Cyp1b1 and NQO1 as was confirmed in the current
experiment [299, 308, 310, 320, 327-329]. Lipid metabolism was shown to be decreased
with CPT1a, Plin2, ACC1 and Fasn. This is inconsistent with previous studies using
TCDD which showed increased lipid accumulation in mouse livers [308, 309, 316, 320,
330, 331]. However, Ovando et al demonstrated that fatty acid binding protein 5 (Fabp5)
which is involved in fatty acid uptake, transport and metabolism, while it is upregulated
in response to dioxin, it is not upregulated in response to PCB 126 [320]. The increase in
GLUT1, HK3, and Pgk1 and concomitant attenuation of GLUT4, glucose-6-phosphate
dehydogenase (G6pd), phosphorylase (pygl), LDHA, and glycogen synthase (GYS2)
gene expression signifies modulation of carbohydrate metabolism. These data suggest an
increase in basal glucose uptake and phosphorylation. G6pd is involved in shunting of
glucose metabolism away from glycolysis and toward lipid synthesis or the pentose
phosphate pathway [6, 23]. Its decreased gene expression in PCB-exposed animals
suggests utilization of glucose for glycolysis while the decrease in LDHA and glycogen
synthase point to increased utilization of glucose metabolites for mitochondrial
respiration and not lactate production. However, genes involved in monocarboxylate
mitochondrial transport and metabolism were not included in the codesets. Dere et al
showed that TCDD-induced AhR activation increases AhR DNA binding at intragenic
regions associated with lipid and carbohydrate metabolism at 2 and 24 hours after
exposure [312]. Nonetheless, alterations in energy homeostasis in response to dioxin is
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time-dependent, and there are no studies that evaluated changes in hepatic gene
expression after 96 hour exposure in response to PCB 126 as in the current experiment.
Dioxin induced hepatic immune cell infiltration was reported by Boverhof et al.
168 hours post exposure, corroborating the current observation of increased adhesion
molecule expression [316]. Insulin-like growth factor binding protein 2 (Igfpb2) is
decreased in both pregnant and non-pregnant mice directly exposed to PCB. This is of
importance because Igfbp2 is thought to mediate some of the glucose normalizing effects
of leptin [332].

Additionally, Igfbp2 overexpression protects against high-fat-diet-

induced obesity, glucose intolerance, and insulin resistance. [333]. Hepatic Igfbp2 mRNA
levels have been shown to correlate with circulating Igfbp2 levels and low serum Igfbp2
are associated with obesity and insulin insensitivity [334-338]. The attenuated expression
of Igfbp2 therefore serves as a mechanism of obesogenic activity of PCBs. Obesityassociated insulin resistance is also associated with inflammation and it is noteworthy
that PCB exposure increased intercellular adhesion molecule (Icam1) expression
independent of pregnancy.
Fetal liver gene expression in response to in utero PCB exposure is as expected
with regard to the classical increase in Cyp1a1, Cyp1b1, and NQO1. Elevated expression
of NQO1 in response to AhR activation has been shown to be dependent upon its binding
to Nrf2. Therefore, it is no surprise that Nrf2 is increased in response to PCB 126
exposure as other Nrf2 responsive genes are also increased. This experiment is the first
to show increased hepatic Dpp4 expression upon PCB 126 exposure. This may be an
event particular to PCBs as many microarray studies using TCDD have not reported
alterations in hepatic Dpp4 gene expression. As Dpp4 degrades incretins such as GLP-1,
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increased Dpp4 expression could result in impaired oral glucose tolerance. Incretins have
a role in potentiating insulin secretion and increasing insulin sensitivity, so it would not
be surprising to observe impairments in oral glucose tolerance as a result of perinatal
PCB exposure.
The 4 month old offspring perinatally exposed to PCB still exhibited augmented
Cyp1a1 gene expression without detectable PCB in their livers although Cyp1b1 and
NQO1 levels were comparable between treatment groups. This phenomenon alludes to
either an epigenetic modification at this particular locus permitting gene transcription in
the absence of exogenous ligand or PCB-induced upregulation of the receptors unknown
endogenous ligand.

Augmented CHOP and Atg7 gene expression is indicative of

physiological stress, particularly stress of the endoplasmic reticulum. Autophagy related
proteins have been shown to be modulated by TCDD exposure in previous studies, but
this is the first report of increased expression of transcriptionally regulated unfolded
protein response protein, CHOP [339]. It could be the case that developmental exposure
to PCB resulted in sustained oxidant production via xenobiotic detoxifying enzymes
which caused eventual disrupted normal hepatic physiology. Endoplasmic reticulum
stress has recently been shown to mediate some of the pathology associated with obesity
and insulin resistance [340-347].
Also, in these aged offspring, again not taking into account gender, there is a
significant decrease in Igf-1 expression.

Tijet et al showed decreased Igf-1 gene

expression in mouse livers upon TCDD exposure and interestingly, this decrease was also
demonstrated in wildtype mice compared to AhR null mice in the absence of ligand
[310]. So it is not entirely surprising that the current exposure model resulted in
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attenuated Igf-1 gene expression in the absence of detectable ligand. Decreased Igf-1
expression in utero can result in intrauterine growth restriction and poor growth during
early life [348, 349]. It is intriguing that decreased Igf-1 expression was not observed in
fetal livers, but only postnatally. Postnatal growth is mediated not only by growth
hormone, but also by Igf-1. These male offspring, upon body composition analysis did
exhibit decreased growth, specifically regarding lean mass, as the males weighed less and
displayed decreased grams of lean mass while relative lean mass was unaltered (Tables
2.3 and 2.5 in Chapter 2).
In conclusion, perinatal PCB exposure alters offspring gene expression in fetuses
and 4 month old offspring. These results illustrate the need to consider the ramifications
of developmental xenobiotic exposure on liver physiology and gene expression and
accentuate the pitfall of inferring effects of TCDD with those of all dioxin-like
compounds.

Finally, further studies are needed to evaluate epigenetic and AhR

coregulatory alterations that contribute to PCB-mediated effects on gene expression in
the absence of detectable ligand within the context of developmental PCB exposure.
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Table 4.1 Ň'DP3DUDPHWHUs

Parameter

Control
(n=9)

PCB
(n=9)

p

Dam Body
Weight (g)

57.22
(1.14)

57.58
(0.96)

0.810

Number of Pups
per litter (g)

11.78
(0.32)

11.00
(0.47)

0.193

Fetal Body
Weight (g)

1.210
(0.026)

1.258
(0.029)

0.226

Placental
Weight (g)

0.095
(0.004)

0.107
(0.005)

0.066
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Table 4.2Ň3UHJQDQW'DP

133.96

PCB/control
ratio
0.52

0.006

790.91

528.69

0.67

0.044

LDHA

3103.82

2092.78

0.67

0.001

CPT-1A

781.70

549.31

0.70

<0.001

Acc1

96.26

70.96

0.74

0.048

SNAT2

376.16

292.17

0.78

0.004

3SDUĮ

426.90

333.57

0.78

0.002

eEF2

1597.35

1826.19

1.14

0.032

Eif3f

237.87

283.87

1.19

0.010

Cyp3a11

5755.76

7439.70

1.29

0.012

Rplp0

1459.02

1907.39

1.31

0.005

Cat

3288.02

4329.15

1.32

0.006

Pgk1

180.87

241.95

1.34

0.012

Dpp4

50.39

71.75

1.42

0.024

Hat1

14.84

22.35

1.51

0.030

Gpx1

1642.59

2526.97

1.54

<0.001

Icam1

22.06

35.07

1.59

<0.001

Gstm4

19.51

39.30

2.01

0.003

Nrf2

116.90

277.02

2.37

<0.001

Cyb5r1

3.91

10.55

2.70

0.031

Cyp1b1

13.83

40.30

2.91

<0.001

NQO1

8.43

28.19

3.35

0.001

MCP1

2.08

11.84

5.69

0.026

Gsta1

2.01

24.36

12.15

0.002

Cyp1a1

1.35

6265.34

4648.60

<0.001

Gene

Control

PCB

IGFBP2

256.07

Plin2
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Table 4.3Ň1RQ-Pregnant

14.47

PCB/Control
Ratio
0.19

0.010

135.04

36.61

0.27

0.015

fasn

10968.28

3253.73

0.30

<0.001

Acc1

2952.94

888.85

0.30

<0.001

G6pdx

581.57

186.37

0.32

0.022

IGFBP2

622.54

292.11

0.47

<0.001

GYS2

1290.93

848.91

0.66

0.011

Mecp2

48.37

36.05

0.75

0.049

PGC1a

83.92

63.73

0.76

0.008

Pygl

5736.99

4387.09

0.76

0.002

Eif3f

1565.58

1903.12

1.22

<0.001

Pgk1

910.35

1110.83

1.22

0.007

eEF2

8784.30

10807.17

1.23

0.002

Hprt1

95.25

118.61

1.25

0.012

Dpp4

898.49

1142.08

1.27

0.001

Tubb5

124.13

160.80

1.30

0.012

1.30

0.032

Gene

Control

PCB

GLUT4

76.98

G6pd2

Gpx1

11491.81 14940.43

p

GLUT1

33.40

60.83

1.82

0.005

Hk3

48.64

97.40

2.00

0.005

Icam1

110.09

245.95

2.23

0.008

Nrf2

632.41

1450.06

2.29

<0.001

NQO1

97.96

250.12

2.55

<0.001

Cyp1b1

79.53

311.07

3.91

0.013

Cyp1a1

12.07

36241.14

3002.50

<0.001
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Table 4.4Ň)HWDO/LYHU

LDHA

6524.58 4670.05

PCB
ratio
0.72

GLUT1

420.59

330.55

0.79

0.045

Gapdh

3285.93 2699.88

0.82

0.004

GCR

197.48

165.98

0.84

0.031

B2m

2345.53 2689.96

1.15

0.018

5[UĮ

242.99

280.12

1.15

0.044

SOD1

2652.56 3099.92

1.17

0.025

+LIĮ

126.23

153.90

1.22

0.010

Prdx1

132.05

161.75

1.22

0.004

Dpp4

58.97

77.87

1.32

0.026

GSTM4

19.26

30.18

1.57

0.015

Nrf2

151.59

244.04

1.61

<0.001

NQO1

24.12

65.86

2.73

<0.001

Cyp1b1

11.36

44.50

3.92

0.002

Cyp1a1

1.30

Gene

Control

PCB

3177.66 2444.82

p
<0.001

<0.001
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Table 4.5Ň2IIVSULQJ/LYHU
PCB/control
ratio
2129.19 1612.56
0.76

0.002

Hif1a

754.07

684.29

0.91

0.044

Atg7

462.78

515.69

1.11

0.028

CHOP

134.94

165.03

1.22

0.028

IGF1R

32.60

52.80

1.62

0.031

Cyp1a1

0.99

874.24

884.85

0.022

Gene
Igf1

Control

PCB
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Table 4.6Ň0DOH2IIVSULQJ

43.33

PCB/control
ratio
0.67

0.011

103.58

0.70

0.029

2271.27 1785.08

0.79

0.040

0.81

0.030

Gene

Control

PCB

Dnmt1

65.03

MCR

148.25

Igf1
FATP4

57.53

46.86
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p

Table 4.7Ň)HPDOH2IIVSULQJ
PCB/control
ratio
0.44

0.043

2018.30 1474.18

0.73

0.027

1055.10

931.09

0.88

0.023

LRP1

6446.90 5668.68

0.88

0.048

Prdx1

1078.49

935.22

0.87

0.004

Pygl

9739.07 8686.65

0.89

0.044

Nrf2

1068.59 1304.09

1.22

0.017

1.62

0.019

Gene

Control

PCB

Hnf6

614.12

272.85

Igf1
Insr

Pparg

70.46

114.08
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Table 4.8 ŇPrimer Sequences for Real-Time PCR
Gene
Cyp1a1 Fwd
Cyp1a1 Rev
NQO1 Fwd
NQO1 Rev
Cltc Fwd
Cltc Rev

Primer Sequence
GAC TTC CAG CCT TCG TGT CA
GGG TTC TTC CCC ACA GTC AG
ACC CCA CTC TAT TTT GCT CC
ACT TAC TCC TTT TCC CAT CCT C
CAG TAA CAA CAA CCC AGA GAG
TCA TAA GCA ACA CAA GCC AG

91

Table 4.9 ŇReal-Time PCR Validation of Hepatic Gene Expression
Relative Quantitya
Mean
(SEM)

Cyp1a1

1940.10**
(470.65)

Nonpregnant
3761.74**
(1010.46)

NQO1

3.84***
(0.33)

2.02**
(0.28)

Gene

Pregnant

3056.80***
(448.24)

Male
Offspring
177.64
(91.18)

Female
Offspring
72.30
(49.56)

2.71***
(0.32)

2.94
(1.22)

0.71
(0.22)

Fetal

a: Gene expression was calculated using 2-¨¨&W method with the mean of the control
group serving as the calibrator
** indicates p<0.01
*** indicates p<0.001
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Table 4.10ŇGenes on 1st Codeset. Underline indicates a putative housekeeping gene and
Bold indicates gene is not included in the other codeset.
Common Name
Acc1
Adipoq
Adipor1
Adrenomedullin
Ahr
Hif1b
Bmal1

Gene Symbol
Acaca
Adipoq
Adipor1
Adm
Ahr
Arnt
Arntl

Gene Name
Fatty acid synthase
Adiponectin
Adiponectin receptor 1
Adrenomedullin
Aryl hydrocarbon receptor
Aryl hydrocarbon receptor nuclear translocator
Brain and muscle ARNT-like protein 1
Aryl hydrocarbon receptor nuclear translocator-like
protein

ATF6
Atg7
B2m
Bax
Bcl2
Cat
MCP1
p16(INK4a)
Cltc
CPT-1A
Creb1
Cyb5r1
Aromatase
Cyp1a1
Cyp1b1
Cyp3a11
CHOP

Atf6
Atg7
B2m
Bax
Bcl2
Cat
Ccl2
Cdkn2a
Cltc
Cpt1a
Creb1
Cyb5r1
Cyp19a1
Cyp1a1
Cyp1b1
Cyp3a11
Ddit3

Dnmt1
Dnmt3a
Dnmt3b
Dpp4/CD26
eEF2
Eif3f
Epx
Esr1

Dnmt1
Dnmt3a
Dnmt3b
Dpp4
Eef2
Eif3f
Epx
Esr1

Activating transcription factor 6
Autophagy related protein 7
beta-2 microglobulin
Bcl-2-associated X protein
B-cell lymphoma 2
Catalase
Monocyte chemotractant protein-1
Cyclin-dependent kinase inhibitor 2A
Clathrin heavy chain 1
Carnitine palmitoyltransferase 1A (liver)
CAMP responsive element binding protein 1
NADH-cytochrome b5 reductase 1
Aromatase
Cytochrome P450, family 1, subfamily A, polypeptide 1
Cytochrome P450, family 1, subfamily B, polypeptide 1

Alpha-methyl acyl-CoA racemase
C/EBP homologous protein (CHOP)
DNA damage-inducible transcript 3
DNA methyl transferase 1
DNA methyl transferase 3a
DNA methyl transferase 3b
Dipeptidyl peptidase 4
Eukaryotic elongation factor 2
Eukaryotic translation initiation factor-3
Eosinophil peroxidase
Estrogen receptor alpha
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Table 4.10 (continued)
ERRa
fasn
Foxa2
Foxo1
G6pc
Gapdh
Gck
Gpx1
Gsk3b
Gsta1
Gstm4
Gusb
GYS1
GYS2
Hat1
Hdac1
Hdac3
Hdac4
HGF
Hif1a
Hprt1
BiP/Grp78

Esrra
Fasn
Foxa2
Foxo1
G6pc
Gapdh
Gck
Gpx2
Gsk3b
Gsta1
Gstm4
Gusb
Gys1
Gys2
Hat1
Hdac1
Hdac3
Hdac4
Hgf
Hif1a
Hprt
Hspa5

Icam1
IDE
Ifng
Igf1
IGF1R
Igfbp1
IGFBP2
Ikbkb

Icam1
Ide
Ifng
Igf1
Igf1r
Igfbp1
Igfbp2
Ikbkb

Il10
Il1a
Il1b
Il2
Il6
Insr
Irs1

Il10
Il1a
Il1b
Il2
Il6
Insr
Irs1

Estrogen-related receptor alpha
Fatty acid synthase
forkhead box protein A2
forkhead box protein O1
Glucose-6-phosphatase, catalytic
Glyceraldehyde 3-phosphate dehydrogenase
Glucokinase
Glutathione peroxidase 1
Glycogen synthase kinase 3 beta
Glutathione S-transferase A1
Glutathione S-transferase mu 4
Beta-glucuronidase
Glycogen synthase 1
Glycogen synthase 2
Histone acetyltransferase 1
Histone deacetylase 1
Histone deacetylase 3
Histone deacetylase 4
Hepatocyte growth factor
Hypoxia-inducible factor 1-alpha
Hypoxanthine-guanine phosphoribosyltransferase
Binding immunoglobulin protein
heat shock 70 kDa protein 5
Intercellular adhesion molecule 1
Insulin-degrading enzyme
Interferon-gamma
Insulin-like growth factor 1
Insulin-like growth factor 1 receptor
Insulin-like growth factor-binding protein 1
Insulin-like growth factor-binding protein 2
Inhibitor of nuclear factor kappa-B kinase
subunit beta
Interleukin-10
Interleukin-1a
Interleukin-1b
Interleukin-2
Interleukin-6
Insulin receptor
Insulin receptor substrate 1
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Table 4.10 (continued)
Irs2
KLF14
LDHA
LDH B
Lep
Lipe
LRP1
MafA /
RIPE3b1
c-MET/HGFR
mtor
Nampt
Nfe2l2
NQO1
PXR1
GCR
Oit1/FAM3D
PEPCK
Pgk1
cPLA2
ZAC/PLAGL1
Plin2
Ppara
Ppard
Pparg
Ppargc1a

Irs2
Klf14
Ldha
Ldhb
Lep
Lipe
Lrp1
Mafa
Met
Mtor
Nampt
Nfe2l2
Nqo1
Nr1i2
Nr3c1
Oit1
Pck1
Pgk1
Pla2g4a
Plagl1
Plin2
Ppara
Ppard
Pparg
Ppargc1a

Prdx1
Prdx6
Ptgs2
RCAN1
Rela

Prdx1
Prdx6
Ptgs2
Rcan1
Rela

Rplp0/36B4
Rxra
SHBG
SIRT1
FATP1
FATP4

Rplp0
Rxra
Shbg
Sirt1
Slc27a1
Slc27a4

Insulin receptor substrate 2
Krüppel-like factor 14
Lactate dehydrogenase A
Lactate dehydrogenase A
Leptin
Hormone-sensitive lipase
Low density lipoprotein receptor-related protein 1
V-maf avian musculoaponeurotic fibrosarcoma
oncogene homolog A
Met protooncogene
Mammalian target of rapamycin
Nicotinamide phosphoribosyltransferase
Nuclear factor (erythroid-derived 2)-like 2
NAD(P)H dehydrogenase [quinone] 1
Pregnane X receptor 1
Glucocorticoid receptor
Family with sequence similarity 3, member D
Phosphoenolpyruvate carboxykinase
Phosphoglycerate kinase 1
Cytosolic phospholipases A2
Zac tumor suppresor gene
Perilipin 2
Peroxisome proliferator-activated receptor alpha
Peroxisome proliferator-activated receptor delta
Peroxisome proliferator-activated receptor gamma
Peroxisome proliferator-activated receptor gamma
coactivator 1-alpha
Peroxiredoxin-1
Peroxiredoxin-6
Prostaglandin-endoperoxide synthase 2
Regulator of calcineurin 1
V-rel reticuloendotheliosis viral oncogene
homolog A
Ribosomal phosphoprotein, large, P0
Retinoid X receptor alpha
Sex hormone-binding globulin
Sirtuin 1
Fatty acid transport protein 1
Fatty acid transport protein 4
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Table 4.10 (continued)
GLUT1
GLUT2
GLUT4
SNAT1
SNAT2
SOD1
SOD3
Opn
TCF7L2
variant 1
Tnf
Tubb5
Txnrd2
UCP1
Vcam1
XBP1

Slc2a1
Slc2a2
Slc2a4
Slc38a1
Slc38a2
Sod1
Sod3
Spp1
Tcf7l2

Glucose transporter 1
Glucose transporter 2
Glucose transporter 4
Sodium-coupled neutral amino acid transporter 1
Sodium-coupled neutral amino acid transporter 2
Superoxide dismutase 1
Superoxide dismutase 3
Osteopontin
Transcription factor 7-like 2

Tnf
Tubb5
Txnrd2
Ucp1
Vcam1
Xbp1

Tumor necrosis factor alpha
Tubulin beta-4A chain
Thioredoxin reductase 2
Uncoupling protein 1
Vascular cell adhesion protein 1
X-box binding protein 1
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Table 4.11ŇGenes on 2nd codeset. Underline indicates a putative housekeeping gene and
Bold indicates gene is not included in the other codeset.
Common Name
Acc1
Adipoq
Adipor1
AFP
Ahr
Hif1b
Bmal1
ATF6
Atg7
B2m
Cat
MCP1
CHRNA7
Cltc
CPT-1A
Creb1
Il8ra
IL8rb
Cyb5r1
Cycs
Cyp1a1
Cyp1b1
Cyp3a11
CHOP
DKK1
Dnmt1
Dnmt3a
Dnmt3b
Dpp4/CD26
eEF2
Eif3f
Estrogen
receptor 1
fasn

Gene Symbol
Acaca
Adipoq
Adipor1
Afp
Ahr
Arnt
Arntl
Atf6
Atg7
B2m
Cat
Ccl2
Chrna7
Cltc
Cpt1a
Creb1
Cxcr1
Cxcr2
Cyb5r1
Cycs
Cyp1a1
Cyp1b1
Cyp3a11
Ddit3
Dkk1
Dnmt1
Dnmt3a
Dnmt3b
Dpp4
Eef2
Eif3f
Esr1

Gene Name
Fatty acid synthase
Adiponectin
Adiponectin receptor 1
Alpha-fetoprotein
Aryl hydrocarbon receptor
Aryl hydrocarbon receptor nuclear translocator
Brain and muscle ARNT-like protein 1
Activating transcription factor 6
Autophagy related protein 7
beta-2 microglobulin
Catalase
Monocyte chemotractant protein-1
Cholinergic receptor, nicotinic, alpha 7
Clathrin heavy chain 1
Carnitine palmitoyltransferase 1A (liver)
CAMP responsive element binding protein 1
Interleukin 8 receptor, alpha
Interleukin 8 receptor, beta
NADH-cytochrome b5 reductase 1
Cytochrome complex, somatic

Alpha-methyl acyl-CoA racemase
C/EBP homologous protein (CHOP)
Dickkopf-related protein 1
DNA methyl transferase 1
DNA methyl transferase 3a
DNA methyl transferase 3b
Dipeptidyl peptidase 4
Eukaryotic elongation factor 2
Eukaryotic translation initiation factor-3
Estrogen receptor alpha

Fasn

Fatty acid synthase

Cytochrome P450, family 1, subfamily A, polypeptide 1
Cytochrome P450, family 1, subfamily B, polypeptide 1
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Table 4.11 (continued)
Fndc5
FoxA2
Foxo1
G6pc
G6pd2
G6pdx
Gapdh
GBE1
glucokinase
Gckr
GLP1R
Gpx1
Gstm4
Gusb
Gyg
GYS1
GYS2
Hat1
Hdac1
Hdac3
Hdac4
HGF
Hif1a
Hk1
Hk2
Hk3
Hnf4a
Hprt1
Hsd11b1
Hsd11b2
Icam1
IDE
Ifng
Igf1
IGF1R
Igf2
Igfbp1
IGFBP2
Il10

Fndc5
Foxa2
Foxo1
G6pc
G6pd2
G6pdx
Gapdh
Gbe1
Gck
Gckr
Glp1r
Gpx1
Gstm4
Gusb
Gyg
Gys1
Gys2
Hat1
Hdac1
Hdac3
Hdac4
Hgf
Hif1a
Hk1
Hk2
Hk3
Hnf4a
Hprt
Hsd11b1
Hsd11b2
Icam1
Ide
Ifng
Igf1
Igf1r
Igf2
Igfbp1
Igfbp2
Il10

Fibronectin type III domain-containing protein 5
forkhead box protein A2
forkhead box protein O1
Glucose-6-phosphatase, catalytic
Glucose-6-phosphate dehydrogenase 2
Glucose-6-phosphate dehydrogenase X-linked
Glyceraldehyde 3-phosphate dehydrogenase
Glycogen-branching enzyme
Glucokinase
Glucokinase regulatory protein
Glucagon-like peptide 1 receptor
Glutathione peroxidase 1
Glutathione S-transferase mu 4
Beta-glucuronidase
Glycogenin
Glycogen synthase 1
Glycogen synthase 2
Histone acetyltransferase 1
Histone deacetylase 1
Histone deacetylase 3
Histone deacetylase 4
Hepatocyte growth factor
Hypoxia-inducible factor 1-alpha
Hexokinase-1
Hexokinase-2
Hexokinase-3
Hepatocyte nuclear factor 4 alpha
Hypoxanthine-guanine phosphoribosyltransferase
Hydroxysteroid 11-beta dehydrogenase 1
Hydroxysteroid 11-beta dehydrogenase 2
Intercellular adhesion molecule 1
insulin degrading enzyme
Interferon-gamma
Insulin-like growth factor 1
Insulin-like growth factor 1 receptor
Insulin-like growth factor 2
Insulin-like growth factor-binding protein 1
Insulin-like growth factor-binding protein 2
Interleukin-10
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Table 4.11 (continued)
Il1a
Il1b
Il6
Insr
Irs1
Irs2
LDHA
LDHB
Lep
Lipe
LRP1
Mecp2
c-MET aka
HGFR
mtor
Nfe2l2
NOX1
NPY1R
NQO1
Lxra
GCR
MCR
Hnf6
PEPCK
Pgk1
Phkb
Phkg
Plin2
Ppara
Pparg
Ppargc1a
PRDM16
Prdx1
Pygl
RCAN1
Rxra
SIRT1
FATP1
FATP4

Il1a
Il1b
Il6
Insr
Irs1
Irs2
Ldha
Ldhb
Lep
Lipe
Lrp1
Mecp2
Met

Interleukin-1a
Interleukin-1b
Interleukin-6
Insulin receptor
Insulin receptor substrate 1
Insulin receptor substrate 2
Lactate dehydrogenase A
Lactate dehydrogenase A
Leptin
Hormone-sensitive lipase
Low density lipoprotein receptor-related protein 1
Methyl CpG binding protein 2
Met protooncogene

Mtor
Nfe2l2
Nox1
Npy1r
Nqo1
Nr1h3
Nr3c1
Nr3c2
Onecut1
Pck1
Pgk1
Phkb
Phkg1
Plin2
Ppara
Pparg
Ppargc1a
Prdm16
Prdx1
Pygl
Rcan1
Rxra
Sirt1
Slc27a1
Slc27a4

Mammalian target of rapamycin
Nuclear factor (erythroid-derived 2)-like 2
NADPH oxidase 1
Neuropeptide Y receptor type 1
NAD(P)H dehydrogenase [quinone] 1
Liver X receptor alpha
Glucocorticoid receptor
Mineralocorticoid receptor
Hepatocyte nuclear factor 6 alpha
Phosphoenolpyruvate carboxykinase
Phosphoglycerate kinase 1
Phosphorylase kinase, beta subunit
Phosphorylase kinase, gamma 1
Perilipin 2
Peroxisome proliferator-activated receptor alpha
Peroxisome proliferator-activated receptor gamma
Pparg coactivator 1-alpha
PR domain containing 16
Peroxiredoxin-1
Glycogen phosphorylase
Regulator of calcineurin 1
Retinoid X receptor alpha
Sirtuin 1
Fatty acid transport protein 1
Fatty acid transport protein 4
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Table 4.11 (continued)
GLUT1
GLUT2
GLUT3
GLUT4
SNAT1
SNAT2
SOD1
SOD3
Sox9
Sry
Tsp1
Tnf
Tubb5
Txnrd2
UCP1
WNT3
WNT7a
XBP1
Zhx2

Slc2a1
Slc2a2
Slc2a3
Slc2a4
Slc38a1
Slc38a2
Sod1
Sod3
Sox9
Sry
Thbs1
Tnf
Tubb5
Txnrd2
Ucp1
Wnt3
Wnt7a
Xbp1
Zhx2

Glucose transporter 1
Glucose transporter 2
Glucose transporter 3
Glucose transporter 4
Sodium-coupled neutral amino acid transporter 1
Sodium-coupled neutral amino acid transporter 2
Superoxide dismutase 1
Superoxide dismutase 3
SRY box-9
Sex determining region of chromosome Y
Thrombospondin 1
Tumor necrosis factor alpha
Tubulin beta-4A chain
Thioredoxin reductase 2
Uncoupling protein 1
Wingless-related MMTV integration site 3
Wingless-related MMTV integration site 7a
X-box binding protein 1
Zinc fingers and homeoboxes protein 2

100

60

40

20

pr
in
g
of
fs

A

ge
d

Fe
tu
se
s

Pr
eg
na

N

on
-p
re
gn
a

nt

0
nt

PCB pmol/mg (wet weight)

PCB 126 levels in Livers

Figure 4.1. Measurement of hepatic PCB 126 levels. Graph illustrates quantity of PCB
126 parent compound in the livers of non-pregnant, pregnant females, fetuses and 4
month old offspring. Lines represent mean and the standard error of the mean. Aged
offspring n=16; all others n=9.
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Non-pregnant

Pregnant
Plin2
CPT-1A
SNAT2
3SDUĮ
Cyp3a11 Cyb5r1
Rplp0 MCP1
GSTA1
Cat
Hat1

Tubb5
GLUT4 GLUT1 Acc1
Pgk1
Hk3
G6pd2
IGFBP2 Gpx1
fasn
Icam1
eEF2
G6pdx
Eif3f
GYS2
Mecp2
PGC1Į
Dpp4
Pygl
Nrf2
Hprt1
NQO1
Cyp1b1
Cyp1a1
LDHA
Gapdh
GSTM4

GLUT1 SOD1
GCR Hif1Į
B2m Prdx1
RxrĮ

Fetal

Figure 4.2 Venn diagram of genes differentially expressed in non-pregnant female mice,
dams and E18.5 pups. Genes are arranged in ascending order beginning with the genes
most down regulated in PCB exposed animals and ending in those genes that are most
upregulated. Further, downregulated genes are underlined. Bold italics indicates that
genes were included in only one of the two codesets.
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CHAPTER 5
DISCUSSION
5.1. General Discussion
5.1.1. IUGR Biweekly exposure to 1 μmole/kg polychlorinated biphenyl (PCB)
126 had no effect on the initial measurement of pup weight, which was at postnatal day
(PND) 3, suggesting that gestational exposure to the pollutant did not restrict fetal
growth. I also mated the animals for 7 days to ensure copulation, but by doing so I
introduced a confounding factor in that it was impossible to determine the length of
gestation which can clearly have an effect on offspring size. Also, because we did not
weigh the pups on PND 0, I cannot conclude for certain that birth weights were not
different due to PCB exposure. I corrected for these factors in AIM 3 by 1) allowing
coitus for a single night, thus all conceptions were on the same day; and 2) measuring
body weights at embryonic day 18 (E18) thereby nullifying variations in gestation length.
Embryonic day 18 fetal weights were not different between groups, confirming the
finding in AIM 1, that biweekly exposure to 1μmole/kg PCB 126 does not cause
intrauterine growth restriction in my mouse model. This of course is not to say that PCB
exposure does not growth restrict the developing fetus as I only used one congener at a
specific dosage. Nonetheless, there are findings in human studies that support that
prenatal PCB exposure does not cause low birth weight [254].
Although the DOHaD hypothesis was predicated on changes of fetal growth and
subsequent disease risk, it is now well accepted that fetal milieu modulation can affect
offspring health irrespective of alterations in fetal growth. Comparable fetal growth in
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between treatment groups means that changes in divergent phenotypes with aging are not
contingent upon decreased birth weight.

This adds to the impact of the presented

research in that most births are of normal birth weight, and the majority of obese and
diabetic individuals had normal birth weights.
5.1.2 Body composition AIM 1 investigated the role of perinatal PCB exposure
on offspring body weight and composition. EchoMRI was first performed at 7 weeks of
age at which time females from PCB exposed offspring showed dose-dependent increases
in percent fat and reductions in percent lean mass while body weights were comparable
between treatment groups.

This metabolically unfavorable profile was no longer

statistically significant at 6 months of age even though the trend was still there regarding
the 1 μmole/kg dose (T-Test p=0.089 and p=0.104 for percent lean and percent fat,
respectively). However, this decline in statistical significance continued. These data are
consistent with published data in humans that demonstrate increased adiposity in young
and adolescent females exposed prenatally to PCBs [208, 239]. Moreover, the one
investigation of prenatal PCB exposure on adult female obesity found no association,
again corroborating the present data on a lack of effect of perinatal PCB exposure on
aged females [242]. Interestingly, ovariectomized rodents exhibit similar changes in
body composition as was observed in females born to PCB exposed dams at 7 weeks of
age. Particularly, ovariectomized rats have increased percent body fat and decreased
percent lean mass [350, 351]. PCBs can modulate estrogen receptor activity [352, 353].
Because the effect on body composition in the females was only observed at the 7 week
time point, when PCB body burden would have been greatest compared to the later time
points, it is possible that the effects on body composition could have been secondary to
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PCB disruption of estrogen activity thereby precipitating body composition profiles
similar to those resulting from ovariectomization.
The male offspring born to PCB-exposed dams displayed dose-dependent
attenuation of lean mass and only trends toward decreased body weights. Statistical
comparison between vehicle exposed and the 1 μmole/kg PCB 126 groups only, showed
significant reductions in body weight in addition to reductions in grams of lean mass for
the duration of the study with no difference in fatness between groups meaning the
reduction in lean mass in the male offspring is attributed solely to diminished lean mass.
The lack of association between perinatal PCB exposure and obesity in male offspring is
also supported by human studies that find significant associations only in female
offspring.

The diminished lean mass is a novel finding that warrants further

investigation. The rate of childhood obesity is increasing alarmingly in America and
perhaps perinatal PCB exposure is a contributing factor. Cross-fostering studies should
be conducted to determine whether in utero or lactational exposure precipitates these
phenotypes.

Perhaps, supplementation of maternal or infant diet with protein can

mitigate the reduction of lean mass.

Further, muscle biopsies can be taken for

histological purposes to evaluate whether the reduction in lean mass is due to decreased
muscle fiber number or size.
5.1.3 Glucose tolerance AIM 2 investigated the role of perinatal coplanar PCB
126 exposure on offspring glucose tolerance. Interestingly the male offspring born to
PCB-exposed dams exhibited impaired glucose tolerance upon an oral glucose tolerance
test. This impairment was not observed, however, at 3 months of age or later time points,
suggesting disrupted glucose homeostasis was due to direct exposure of PCBs as aging
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would indeed decrease the body burden. The fact that impaired glucose tolerance was
not observed late in life also excludes a possibility of developmental programming of
glucose intolerance as would be predicted by the DOHaD Hypothesis. Animal studies
have shown impaired glucose tolerance mediated by insulin resistance in male mice
exposed to coplanar PCBs 77 and 126 [214]. Unfortunately an insulin tolerance test was
not performed at this time so although likely, it is uncertain that PCB-induced impairment
in glucose homeostasis was caused by insulin resistance. Initially, it was thought that this
impairment was a result of diminished lean mass, but in the present study, the body
composition phenotype persisted while the impairment in glucose tolerance did not.
Experimentally, there were some factors that may compromise the glucose
tolerance results in the males. The male vehicle exposed offspring fought excessively
and many had to be single-housed because of this. The stress of fighting and being
single-housed could have impacted the glucose tolerance results. The PCB-treated males
experienced delayed and more mild aggression resulting in unmatched housing
conditions between groups. Additionally, some of the vehicle treated males exhibited
severe disruption of glucose homeostasis with 3 hour fasted glucose levels above 300
mg/dL. This observance, as I understand it via personal communication, is a very rare
one.

Maternal ingestion of the safflower oil vehicle apparently disrupted glucose

homeostasis in male offspring. Several studies use corn oil as a vehicle, while others lace
a cookie with PCB. Perhaps these methods of PCB exposure should be used in future
experiments in order to circumvent perinatal safflower oil-induced ablation of glucose
homeostasis.
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Female offspring exhibited impaired glucose tolerance only upon aging, with the
first observance of glucose intolerance being at 6 months of age. This impairment
persisted for the duration of the study which is suggestive of developmental
programming. However, this impairment was most pronounced at the first time point of
the glucose tolerance test, at 15 minutes. This spike in blood glucose at 15 minutes and a
rapid recovery is not characteristic of a glucose tolerance curve with insulin resistance or
impaired insulin secretion.

A glucose tolerance test with i.p. administered glucose

revealed comparable blood glucose regulation. These data suggest that PCB-mediated
attenuation of glucose tolerance was not due to glucose-stimulated insulin secretion.
Further, insulin tolerance tests demonstrated similar rates of decline of blood glucose
between vehicle and perinatal PCB-exposed female offspring, thus confirming the
absence of insulin resistance. An early event in glucose appearance may have been
mediating the effects such as increased rate of gastric emptying, portal vein shunting by
the ductus venosus, impaired first pass hepatic glucose uptake, delayed hepatic glucose
production inhibition, or incretin dysfunction. The pyruvate tolerance test demonstrated
no difference in hepatic glucose output via gluconeogenesis. The glucagon-like peptide
(GLP) -1 receptor antagonism study is inconclusive as it was not controlled for properly
due to low number of animals remaining and so should be repeated with larger sample
size. In addition to repeating the GLP-1 receptor antagonism study, GLP-1 receptor
agonist Exendin-4 should be used to further evaluate the involvement of this incretin in
the observed phenotype. Future studies should also use a different vehicle because it is
likely safflower oil had an effect on the female offspring because of the profound effects
on males. A paraceptamol gastric emptying test could be performed to investigate if
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different rates of gastric emptying are causing the increase in blood glucose at the early
15 minute time point. Cross fostering experiments again would aid in determining the
significance of in utero versus postnatal exposure. Because poor diet is prevalent in
developed countries and causal for obesity and diabetes, I propose weaning the a subset
of the offspring onto a Western Diet determine if this exacerbates either PCB-induced
obesity or impaired glucose tolerance.
5.1.4 Hepatic gene expression Absolute quantification of mRNA of liver tissue
from vehicle and PCB treated pregnant and non-pregnant dams, E18 fetuses and 4 month
old male and female offspring was measured using NanoString nCounter technology.
The goal was not to make a direct comparison between PCB-induced effects during
pregnancy versus those female mice that were not impregnated so as to investigate the
effect of pregnancy on PCB-induced modulation of hepatic gene expression, therefore,
two-way ANOVA’s were not performed. The goal was to uncover possible mechanisms
involved in disruption of glucose homeostasis as a result of maternal PCB exposure.
Insulin-like growth factor binding protein 2 (IGFBP2) has been shown to play a role in
both development of obesity and glucose tolerance evidenced by attenuated development
of age and diet associated obesity and glucose intolerance in human-IGFBP2
overexpressing mice [333]. The decreased IGFBP2 gene expression was observed in
PCB exposed female mice, indicating susceptibility to both obesity and perturbed glucose
regulation. Further, euglycemic clamp studies reveal that IGFBP2 improves hepatic
insulin sensitivity [334]. Moreover, increased dipeptidyl peptidase 4 (DPP4) expression
in female livers, fetal livers, and the interaction of Dpp4 with gender reveal susceptibility
of females to the glucoregulatory effects of incretins (reviewed in [322] and [323]).
108

DPP4 degrades incretins, and by reducing systemic levels, their beneficial effects may be
compromised. These female specific changes in gene expression illustrate a role of PCBs
in both obesogenicity and oral glucose intolerance. Finally, aged offspring displayed
increased expression of endoplasmic reticulum stress response proteins DNA damageinducible transcript 3 (CHOP) and autophagy related protein 7 (Atg7). Obesity causes
chronic ER stress in liver and other tissues in humans and animal models [340-342].
Recent evidence demonstrates a role of ER stress in propagating metabolic derangements,
and mitigation of ER stress has been shown to improve insulin sensitivity and glycemic
control [341, 343-347]. The putative mechanism is that ER stress signaling causes c-Jun
N-terminal Kinase (JNK) activation which attenuates insulin signal transduction and
consequently insulin sensitivity [354-356]. However, the present study only showed
increases in two ER stress-related gene transcripts. The activities of many ER stress
proteins such as X-box-binding protein-1 (Xbp1) and activating transcription factor
(ATF) 6 are not transcriptionally regulated, therefore future studies should utilize
immunohistochemical techniques to further elucidate the extent of PCB-programmed ER
stress, as well as Western blotting for phosphorylated JNK and components of insulin
signaling.
A role of dioxins in gut homeostasis is emerging. The immune system of the gut
plays a major role in whole body immunity as many foreign particles are ingested yet do
not elicit immune response. Also, the gut is home to over a trillion commensal bacteria
whose presence in the blood stream can cause many disorders including sepsis and death.
The AhR is expressed abundantly in intestinal epithelial cells and may play a role in oral
tolerance and gut barrier maintenance [357, 358]. Moreover, toll-like receptors that
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recognize bacterial components have been shown to be involved in energy homeostasis
[359]. Research also shows that the composition of the gut microbiome can predispose
the host to obesity [360, 361]. Just this year, Choi et al. has shown that PCB ingestion
alters the gut microflora to one which is metabolically unfavourable; the study also
showed that exercise can attenuate the observed negative changes in bacterial
composition [362].
5.1.5 Limitations One limitation of the presented research is that only one toxicant
was used. Humans are exposed to a plethora of dietary xenobiotic compounds. Toxic
equivalency factors are AhR binding affinities relative to dioxin and are used to provide
an estimation of AhR-mediated toxicity. However, some xenobiotics do not bind the
AhR but still mediate toxicological effects. Another limitation is that my exposure model
is not consistent with the human experience in that humans have chronic low level
exposure over many years that produce reported body burdens while my model used an
acute exposure model in order to decrease body burden variability and expedite the
findings. Because my dissertation is focused on perinatal effects of PCBs on offspring
body composition and glucose tolerance, experimental animals were not exposed to PCBs
after weaning. However, feeding the offspring a Western diet containing PCBs would
more precisely mimic dietary exposure seen in humans and perhaps the results would
provide for better extrapolation.

Copyright © Cetewayo Saif Rashid 2013
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Appendix
Pilot Study
Introduction: The experiments presented in this dissertation investigates the effects of
maternal PCB exposure on offspring body composition and glucose tolerance and further,
investigates changes in hepatic gene expression. Before experiments were performed,
there was a selection of dosage that occurred. Here I present data regarding the selection
of our dose and the frequency of dosing. The dosing was selected based upon systemic
inflammation occurring as a result of PCB exposure.

Further, a preliminary study

investigated the effects of maternal PCB exposure on fecundity.
Materials and Methods:

The experiments were performed in accordance with an

approved Institutional Animal Care and Use Committee protocol at the University of
Kentucky. ICR/CD-1 mice were purchased from Taconic. In selection of my dose, mice
were oral gavaged with either tocopherol-stripped safflower oil (Dyets # 403952
Bethlehem, PA) or PCB 126 (3, 3’, 4, 4’, 5-pentachlorobiphenyl from AccuStandard C126N, New Haven, CT).

Concentrations of 0, 1, and 5 μmole/kg PCB 126 was

administered to female ICR mice via oral gavage and serum was collected either 24 hours
or one week post exposure in separate cohorts. Serum cytokine levels were measured
using Bio-Plex Pro Mouse Cytokine 23-Plex Panel (Bio-rad M60-009RDPD). Based
upon the findings regarding PCB-induced inflammation, a preliminary study was
conducted to investigate their effects on fecundity. Naïve females were purchased from
Taconic and acclimated for one week prior to PCB exposure. Female mice were orally
gavaged with either vehicle (tocopherol-stripped safflower oil) or PCB 126 at
concentrations of 1 and 5 μmole/kg beginning 2 weeks prior to mating. This exposure
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was repeated weekly for a total of 5 doses. The frequency was such that mice were
exposed twice prior to mating, once at the commencement of mating, and twice again
during gestation.

Mice were not exposed during lactation.

Oneway ANOVA was

performed to test for statistical significance.
Results
Exposure to PCB 126 resulted in an acute inflammatory response with proinflammatory
cytokines, TNF-Į ,O-1 and Il-6, being elevated 24 hours after exposure but not at one
week post exposure although these effects were not statistically significant (Figure S.1AC).

Because the inflammatory response appeared to be mitigated after one week, I

exposed mice weekly to PCB. Weekly PCB exposure had dire effects on fecundity and
rearing with PCB exposure affecting the number of pregnancies, and PND 2 litter
number, size and mean body weight (Table S.1). On PND 28, at which time mice were
weaned, there was a marked effect on body size specifically in the male offspring (Figure
S.1D).
Discussion
This weekly dosing appeared to cause overt toxicity which was not my goal. My goal is
to investigate subtle changes in PCB exposure on offspring metabolic parameters. These
effects on offspring health were not conducive to subsequent experimentation due to its
confounding effect on survival. As a result, PCB exposure was lessened in frequency.
Also the 5 μmole/kg dose was removed from any further experimentation.
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Table S.1 ŇPilot Study: Weekly PCB Exposure on Fecundity and Survival

Dose of
PCB 126
(μmole/kg)

#a
Pregnancies

0

Postnatal Day 2
Mean
(SEM)
# litters

Pups/litter

Body
weight

19/20

19

10
( 0.485)

2.207
(0.056)

1

17/19

6

3.5*
(0.428)

1.967
(0.163)

5

3/18b

1

5
(0.000)

2.560
(0.000)

P

-

-

0.002

0.032

*, ** significantly different from control, p<0.05 and p<0.01, respectively.
a: Number of pregnancies based upon litter delivery
b: One of these pregnancies is based on body weight gain and not litter delivery
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IL-1ȕ
2

0 μmole/kg
5 μmole/kg

p=0.089
p=0.247

1.5

B

1
0.5

24 hr

C
Relative Quantity

2
1.5

p=0.107

p=0.454

1
0.5
0

0

24 hr

1 wk

D

Il-6
5

TNF-Į

1 μmole/kg

Relative Quantity

Relative Quantity

A

1 wk

Control

p=0.076

4
3

p=0.083

2
1

PCB

0
24 hr

1 wk

Figure S.1 Effect of PCB exposure on inflammation and offspring size. In selection of
a dose, PCB 126 or vehicle was administered to female ICR mice via oral gavage. Serum
cytokine levels were measured 24 hours after exposure and one week post exposure in
separate cohorts. A-C show the amount of inflammatory cytokines in serum as fold
change to vehicle exposed animals. The p values were determined via Oneway ANOVA.
D is a picture showing the size difference among male offspring between treatment
groups at weaning, which was at PND 28.
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Much of the data and text from Chapter 2 is “Reprinted from Journal of Pediatric
Biochemistry, vol. 3 , Rashid CS, Carter LG, Hennig B, Pearson KJ. Perinatal
polychlorinated biphenyl 126 exposure alters offspring body composition, 47-53,
Copyright (2013), with permission from IOS Press”
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